CA1140118A - Substituted n-iminomethylpiperidines - Google Patents
Substituted n-iminomethylpiperidinesInfo
- Publication number
- CA1140118A CA1140118A CA000324324A CA324324A CA1140118A CA 1140118 A CA1140118 A CA 1140118A CA 000324324 A CA000324324 A CA 000324324A CA 324324 A CA324324 A CA 324324A CA 1140118 A CA1140118 A CA 1140118A
- Authority
- CA
- Canada
- Prior art keywords
- group
- phenyl
- methyl
- member selected
- loweralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HPYKRLQBMUPOFA-UHFFFAOYSA-N piperidin-1-ylmethanimine Chemical class N=CN1CCCCC1 HPYKRLQBMUPOFA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 119
- -1 diphenylhydroxymethyl Chemical group 0.000 claims description 111
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 65
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 60
- 239000002253 acid Substances 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 57
- 238000007792 addition Methods 0.000 claims description 54
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 42
- 231100000252 nontoxic Toxicity 0.000 claims description 42
- 230000003000 nontoxic effect Effects 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 24
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 21
- LUYLEMZRJQTGPM-UHFFFAOYSA-N 4-benzhydrylpiperidine Chemical compound C1CNCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 LUYLEMZRJQTGPM-UHFFFAOYSA-N 0.000 claims description 14
- 239000004305 biphenyl Substances 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- IHQJXDLHKZENCY-UHFFFAOYSA-N 4-benzhydrylpiperidine-1-carbaldehyde Chemical compound C1CN(C=O)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 IHQJXDLHKZENCY-UHFFFAOYSA-N 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 235000010290 biphenyl Nutrition 0.000 claims description 11
- 125000006267 biphenyl group Chemical group 0.000 claims description 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 11
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 10
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- WKOWVPWMBLXPNA-UHFFFAOYSA-N (4-benzhydrylpiperidin-1-yl)methanimine Chemical compound C1CN(C=N)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 WKOWVPWMBLXPNA-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 claims description 2
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- GLJKLMQZANYKBO-UHFFFAOYSA-N n-octylacetamide Chemical compound CCCCCCCCNC(C)=O GLJKLMQZANYKBO-UHFFFAOYSA-N 0.000 claims description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 22
- 238000004519 manufacturing process Methods 0.000 claims 21
- 239000000126 substance Substances 0.000 claims 21
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 6
- DHLFRMXOIRBEJT-UHFFFAOYSA-N 1-(3-benzhydrylpiperidin-1-yl)-n-octylmethanimine Chemical compound C1N(C=NCCCCCCCC)CCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 DHLFRMXOIRBEJT-UHFFFAOYSA-N 0.000 claims 2
- MGJDROYKVQVIDO-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-[(4-chlorophenyl)methyl]methanimine Chemical compound C1=CC(Cl)=CC=C1CN=CN1CCC(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MGJDROYKVQVIDO-UHFFFAOYSA-N 0.000 claims 2
- RRQHGUAGZHTIQO-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-hexylmethanimine Chemical compound C1CN(C=NCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 RRQHGUAGZHTIQO-UHFFFAOYSA-N 0.000 claims 2
- DWTVABJWHCKNQE-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-octylethanimine Chemical compound C1CN(C(C)=NCCCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 DWTVABJWHCKNQE-UHFFFAOYSA-N 0.000 claims 2
- DROSUKHUMWESGP-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-prop-2-ynylmethanimine Chemical compound C1CN(C=NCC#C)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 DROSUKHUMWESGP-UHFFFAOYSA-N 0.000 claims 2
- VOUZFWAAEUFGQN-UHFFFAOYSA-N 3-benzhydrylpiperidine-1-carbothialdehyde Chemical compound C1(=CC=CC=C1)C(C1CN(CCC1)C=S)C1=CC=CC=C1 VOUZFWAAEUFGQN-UHFFFAOYSA-N 0.000 claims 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 2
- GEXJFIOPGAASTP-UHFFFAOYSA-N $l^{1}-azanylethane Chemical compound CC[N] GEXJFIOPGAASTP-UHFFFAOYSA-N 0.000 claims 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 claims 1
- OBNAPUIVNAHAPU-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-ethylmethanimine Chemical compound C1CN(C=NCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 OBNAPUIVNAHAPU-UHFFFAOYSA-N 0.000 claims 1
- JXPCRJDMUSNASY-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-octylmethanimine Chemical compound C1CN(C=NCCCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 JXPCRJDMUSNASY-UHFFFAOYSA-N 0.000 claims 1
- XCYGHYMVPSURQN-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-propan-2-ylmethanimine Chemical compound C1CN(C=NC(C)C)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 XCYGHYMVPSURQN-UHFFFAOYSA-N 0.000 claims 1
- IQAXPGYCYWUFEL-UHFFFAOYSA-N 1-[4-[(4-methoxyphenyl)-phenylmethyl]piperidin-1-yl]-n-octylmethanimine Chemical compound C1CN(C=NCCCCCCCC)CCC1C(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 IQAXPGYCYWUFEL-UHFFFAOYSA-N 0.000 claims 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 1
- JKKZWGDWHCKEEJ-UHFFFAOYSA-N 4-[[1-(4-methoxyphenyl)cyclohexa-2,4-dien-1-yl]methyl]piperidine-1-carbaldehyde Chemical compound C(=O)N1CCC(CC1)CC1(CC=CC=C1)C1=CC=C(C=C1)OC JKKZWGDWHCKEEJ-UHFFFAOYSA-N 0.000 claims 1
- KAXQSKNDPOZXIA-UHFFFAOYSA-N 4-[hydroxy(diphenyl)methyl]piperidine-1-carbothialdehyde Chemical compound OC(C1CCN(CC1)C=S)(C1=CC=CC=C1)C1=CC=CC=C1 KAXQSKNDPOZXIA-UHFFFAOYSA-N 0.000 claims 1
- YNZMNPCUULSOIH-UHFFFAOYSA-N 4-benzhydrylidenepiperidine-1-carbothialdehyde Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)=C1CCN(CC1)C=S YNZMNPCUULSOIH-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims 1
- HEZYPWDHDAPLSB-UHFFFAOYSA-N ethyl methanimidate Chemical compound CCOC=N HEZYPWDHDAPLSB-UHFFFAOYSA-N 0.000 claims 1
- ATZIPACKTBIFAX-UHFFFAOYSA-N ethyl propanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CC ATZIPACKTBIFAX-UHFFFAOYSA-N 0.000 claims 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- AKWHYGRMHWTPJR-UHFFFAOYSA-N naphthalene-2-sulfonic acid;4-[[1-(octyliminomethyl)piperidin-4-yl]-phenylmethyl]phenol Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21.C1CN(C=NCCCCCCCC)CCC1C(C=1C=CC(O)=CC=1)C1=CC=CC=C1 AKWHYGRMHWTPJR-UHFFFAOYSA-N 0.000 claims 1
- 229940117803 phenethylamine Drugs 0.000 claims 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 230000027119 gastric acid secretion Effects 0.000 abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 239000007787 solid Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229960004592 isopropanol Drugs 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- JPUTTYRVDANTBN-UHFFFAOYSA-N ethyl methanimidate;hydrochloride Chemical compound Cl.CCOC=N JPUTTYRVDANTBN-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- SDSVJQZSTMOVFF-UHFFFAOYSA-N 4-benzhydrylpiperidine-1-carbothialdehyde Chemical compound C1CN(C=S)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 SDSVJQZSTMOVFF-UHFFFAOYSA-N 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 5
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- 229910003446 platinum oxide Inorganic materials 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000004341 endo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@@]2([H])* 0.000 description 3
- 125000004340 exo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@]2([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003822 preparative gas chromatography Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- MXBDXXYGMKLQJM-WLHGVMLRSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-dodecylmethanimine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C=NCCCCCCCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 MXBDXXYGMKLQJM-WLHGVMLRSA-N 0.000 description 2
- KRTMQDOLKIGPAH-WLHGVMLRSA-N 1-(4-benzhydrylpiperidin-1-yl)-n-octylmethanimine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C=NCCCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 KRTMQDOLKIGPAH-WLHGVMLRSA-N 0.000 description 2
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- LWGGQOXUXCRPLU-UHFFFAOYSA-N 4-fluoren-1-ylidenepiperidine Chemical compound C1CNCCC1=C1C2=CC3=CC=CC=C3C2=CC=C1 LWGGQOXUXCRPLU-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 101150007604 TRIM44 gene Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- SKFLCXNDKRUHTA-UHFFFAOYSA-N phenyl(pyridin-4-yl)methanone Chemical compound C=1C=NC=CC=1C(=O)C1=CC=CC=C1 SKFLCXNDKRUHTA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- HAFWELDDNUXLCK-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O HAFWELDDNUXLCK-TYYBGVCCSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- VPAFQIBPKJHWPX-UHFFFAOYSA-N 1-(4-benzhydrylpiperidin-1-yl)-N-ethylmethanimine oxalic acid Chemical compound C(C(=O)O)(=O)O.C1(=CC=CC=C1)C(C1CCN(CC1)C=NCC)C1=CC=CC=C1 VPAFQIBPKJHWPX-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical compound C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
- DYQFCTCUULUMTQ-UHFFFAOYSA-N 1-isocyanatooctane Chemical compound CCCCCCCCN=C=O DYQFCTCUULUMTQ-UHFFFAOYSA-N 0.000 description 1
- YEZHGQZHWKJPCM-UHFFFAOYSA-N 1-isothiocyanatooctane Chemical compound CCCCCCCCN=C=S YEZHGQZHWKJPCM-UHFFFAOYSA-N 0.000 description 1
- LYUPJHVGLFETDG-UHFFFAOYSA-N 1-phenylbutan-2-ol Chemical compound CCC(O)CC1=CC=CC=C1 LYUPJHVGLFETDG-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GZWGFZAHEBTXFN-UHFFFAOYSA-N 4-benzhydryl-n-octylpiperidine-1-carbothioamide Chemical compound C1CN(C(=S)NCCCCCCCC)CCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 GZWGFZAHEBTXFN-UHFFFAOYSA-N 0.000 description 1
- RFKFEUGUPZHBKZ-UHFFFAOYSA-N 5-[bis(2-chloroethyl)aminomethyl]-1h-pyrimidine-2,4-dione;hydrochloride Chemical group Cl.ClCCN(CCCl)CC1=CNC(=O)NC1=O RFKFEUGUPZHBKZ-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101000837192 Drosophila melanogaster Teneurin-m Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000982822 Ficus obtusifolia Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 101150037462 ccmE gene Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- ZJXHGGKLNYDCHZ-UHFFFAOYSA-N ethyl n-octylethanimidate Chemical compound CCCCCCCCN=C(C)OCC ZJXHGGKLNYDCHZ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- BVUQKCCKUOSAEV-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=[C-]C=C1 BVUQKCCKUOSAEV-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- SKECXRFZFFAANN-UHFFFAOYSA-N n,n-dimethylmethanethioamide Chemical compound CN(C)C=S SKECXRFZFFAANN-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- ZBWPKQRQZDZVSF-UHFFFAOYSA-N n-octylformamide Chemical compound CCCCCCCCNC=O ZBWPKQRQZDZVSF-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005485 noradamantyl group Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- RLXDCJUIXHSXQD-UHFFFAOYSA-N oxalic acid;hydrate Chemical compound O.OC(=O)C(O)=O.OC(=O)C(O)=O RLXDCJUIXHSXQD-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ABSTRACT
SUBSTITUTED N-IMINOMETHYLPIPERIDINES
Substituted N-iminomethylpiperidines are dis-closed which are useful for the inhibition of gastric acid secretion.
SUBSTITUTED N-IMINOMETHYLPIPERIDINES
Substituted N-iminomethylpiperidines are dis-closed which are useful for the inhibition of gastric acid secretion.
Description
~401.1~3 -SUBSTITUTED N-IMINOMETXYLPIPERIDINES
. .
BACKGRO~ND o~ TEE INVENTION
.
Unsubstituted ~-iminomethylpiperidine is dis-closed in United States Patent No. 2,615,023, but said compound does not inhibit gastric acid secretion even at dose~ four times or greater than those at which the subject compounds are active. It has now surprisingly been discovered t~at certain substituted N-Lminomethyl-piperidines are effective inhibitors of gastric acid secretion.
SUMMARY OF THE INVENTION
Description of the Compounds~
The present invention comprises substituted N-iminomethylpiperidines of Formula ~
R
Rl >~ NC=NR3 . A ~ R2 (I) wherein:
Rl taken individually is a member selected from the group consisting of hydrogen; phenyl;
phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, h~X~ and halo; ~yl(Cl~C4tloweraIkyl; l-phenyl(C7-Cg)-loweralkyl; p~enyltCl-C4Sloweralkyl and l-phenyl(C7-C9~-loweralkyl in which said phenyl is substituted with from 114V~
one to three members each selected from the group con-sisting of loweralXyl, loweralkoxy, hydroxy, halo, and phenyl, ~rovided that no more than one member is phenyl;
diphenyl(Cl-C4~loweralkyl; diphenyl(Cl-C4)loweralkyl S wherein at least one of said phenyls is substituted with from one to three memhers each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is pheny}; diphenylhydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls i5 gubstituted with from one to three members each selected from the group consi~ting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
~C ~ and wherein n is 0, 1, or 2 and E is H or OH;
A t~ in~ivi~E~ly is a memker selected frcm the ~roup conslcting of ~x~en, acetyl, an~ phenyl, provided that when A is acetyl or phenyl, Rl i5 a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
Rl and A taXen together is a member selected ~rom the group consisting o~ benzhydrylidene and compounds of ~ormulae:
(C ~ and wherein n is 0, 1, or 2;
~ '~ individhally is a ms~ sel~ from the grDUD oonsi~ing of ~XX~n; methyl; diphenylmethy~; diphenyl--methyl wher~in at least one of the phenyl groups is sub-stituted with from one to three mem~ers each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenyl~
hydroxymethyl wherein at least one of said phenyls is su~stituted with from one to three members each selected from ~he group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member i~ phenyl; and a compound of formula:
~.
~C~
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen;
Rl' and B taken together is a member selected from the group consisting of ~enzhydrylidene and a compound of ~ormula:
(CH
wherein n i3 0, l, or 2.
Rl'taken individually is a m3mber sele~ fLal~the grou~ consistmg of hy~ , diphenylmet~yl; diphenylmethyl wherein at least one of said phenyls is substituted with frcm one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, pro-vided that no more than one m~oer is phenyl; diphenyl-hydroxymethyl; diphenylhydroxymethyl wherein at least ~40~ 18 one of sa~d phenyls is substituted with from one to three members each selected ~rom the group consisting of loweralkyl, loweralko~y, hydroxy, halo, and phenyl, provided that no more than one mernber is phenyl; and compounds of formulae:
~ H and ~ H
wherein n is 0, 1, or 2:
D taken individually is hydrogen;
Rl" and D taken together is benzhydrylidene.
R2 is a member selected from the group consisting of hydrogen and Cl-C4 loweralkyl; and R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenylloweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; diphenyl(Cl-C4)10weralkyl; di-phenyl(Cl-C4)loweralkyl in which at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl;
alkenyl; and alkynyl; provided that at least one of said Rl, R'l and R"l is other than hydrogen and further provided that when R"l is other than hydrogen Rl, and R'l, and A are each hydrogen; when R'l is hydrogen only one of Rl and R"l is other than hydrogen; when R'l is methyl Rl is other than hydrogen and R"l is hydrogen; and when R'l is other than hydrogen or ethyl Rl, R"l and A are each hydrogen.
As used herein~loweralkyl and loweralkoxy may be straight or branched chain saturated aliphatic hydrocarbons having from one to eight carbon atoms, such as for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, and the like lower-alkyls, and, respectively, the corresponding loweralkoxys, e.g., methoxy, r~ ~
1~L~V~.18 ethoxy, propoxy, isopropoxy, butoxy, pentoxy, and the liXe. The term "Cl-C4 loweralkyl" includes those lower-alkyls having from one to four carbon atoms, such as for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec butyl, and the like. The terms "phenyl-(Cl-C4)loweralkyl" and "diphenyl(Cl-C4)loweralkyl" include only those compounds where the phenyl group( 5 ) are bonded to the terminal carbon atom of a straight chain loweralkyl, such as 2-phenethyl, 4-phenylbutyl, 4,4-diphenylbutyl, 3,3-diphenylpropyl, and the like. The term n l-phenyl-(C7-Cg)loweralkyl" includes groups having the following general formula:
~1 (C~ 2)m c~3 where m is 5, 6,~r 7. me tenm "alkyl" includes straight or branched chain saturated aliphatic hydrocarbons having up to about sixteen carbon atoms, such as for example, the a~o~e mentioned loweralkyls and fsrther such radicals as hexyl, heptyl, octyl, nonyl, decyl, dodecyl, hexadecyl, and the like. The term "cycloalkyl" includes mono-, bi-, and tricyclic saturated and unsaturated aliphatic hydro-carbons having up to about ten carbon atoms, such as for example, cyclohexyl, adamantyl, l-adamantyl-methyl, exo-norbornyl, endo-norbornyl, noradamantyl, anti-7-norbornenyl, and the like. The terms "alkenyl" and "alkynyl" include straight and branched chain hydro-carbons having from two to about eighteen carbon atoms and at least one double or triple bond, respectively, such as for example, allyl, methallyl, l-propargyl (l-propynyl), 2-pentenyl, and the like. The term "halo"
includes fluoro, chloro, bromo and iodo.
Methods of Preparation The compounds of Formula I may generally be prepared by reacting together: a) an appropriately-6ubstituted piperidine of Formula (II) with an appropriate activated amide (Formula III), or b) an appropriate primary amine of Formula (VII) with an activated N-acyl ~Vt ~
piperidine of Formula (VI), said activation in either case having been achieved by treatment of the respective amide with a suitable activating agent selected from, for example, phosgene, Me30 BF4 , Et30 BF4 , (MeO)2S0 MeOS02F, POCl~, PC15 and the like.
Included in the terms n amide n and "N-acyl-piperidine" as used herein are the corresponding thio derivatives in which the carbonyl oxygen has been re-placed by sulfur. In the case of the thio derivatives, there are additional suitable activating agents which may be employed, such as for example, loweralkyl halides (methyl halide being preferred), methyl tosylate, methyl sulfonic acid esters te.g., methyl methanesulfonate) methyl trifluoromethylsulfonate, and the like.
The activated reactant o~ Formula (III) may be in either free base or acid addition salt form.
Specific preparative routes are given below:
~ ) The compounds of Formula (I) may be pre-pared by reacting the appropriately-substituted piperidine of Formula (IT) with an appropriate imidate ester of Formula (III). The methyl and ethyl esters are preferred.
The substituted piperidine and the imidate ester (which may be present in either free base or acid addition salt form, the latter being shown) are stirred together in a suitable oryanic solvent such as, for example, a halo-carbon (e.g., carbon tetrachloride, chloroform, 1,2-dichloroethane, and the like), a loweralkanol (e.g., methanol, ethanol, isopropanol, and the like), an aromatic hydrocar~on (e.g., benzene, xylene, toluene, and the like), dimethylsu~foxide, and the like. The temperature of the reaction is preferably from about 0 to about 25C, and in some cases may be carried out as high as 50C, but in any event the temperature of the reaction must not be high enough to decompose significant amounts of the imidate e~ter. The resulting product may be isolated and purified by techni~ues known in the art, e.g., by stripping off the solvent and recrystallizing the desired produet in the free base or acid addition salt form.
The above reaction ~cheme may be illustrated by the 1147~ 18 following~ wherein Al B, D, Rl, Rl', Rln, R2, and R3 are as previously defined, Z is selected from the group con-sisting of loweralkoxy (preferably methoxy and ethoxy), loweralkyl-S- (preferably methylthio), chloro, and C12(0)P0-, and X is a member selected from the group consisting o~ halid~, BF4, FS03, and CH30S03. Addi-tionally, when Z is loweral~yl-S-, X may also be a member selected from the group consisting of (4-methylphenyl)S03, CH3S03, and CF3S03.
Rl' B 1 Rl~ B Ri ~ D \~ ~ D
Rl ~ NH + ZC=NR3 HX 3 ~ NC2NR3 ~ III) tI) The compounds of Formula tI) wherein R2 is hydrogen may also be-prepared ~y an analogous route by substituting an appropriate compound of Formula (IIIA) or (IIIB) for the imidate ester of Formula (III). If the former is used, the resulting thiourea is then re-duced (e.g., with Raney nickel) to give the desired com-pound. If the latter is used, silver c~loride is em-ployed as catalyst. These reaction schemes are illus-trated by the following:
....
R ' B'`l R ~
A ~ NH + R3N'C=S ~--_~thiOurcl reduction)(I) (R
(II) (IIIA) ~ ..
R ' B'`l R~
A ~ NH + R3N-C cat~l~ti~ l ) (I) (R2=H) tII) (IIIB) M~ 335 1~4V~l~
B) The compounds of Formula (I) may also be prepared by reac~i~g a suitably-substi~uted piperidine of ~ormula (II) with acetic formic anhydride or N,N-diloweralkylthioformamide (for R2=H~ or a Cl-C4 loweralkyl anhydride ~for R2=Cl-C4 loweralkyl), the anhydride pre-ferably being present in excess. The piperidine and anhydride or thio~n~m~de are combined with cooling and æe allowed to stir for about 18 hours. The resulting reac-tion mixture, either dissolved in an organic solvent ~elected from t~e aforementioned halocarhon and alipha-tic hydrocarhon ~olvents or ~ithout the addition of solvent, is then treated ~lt~ an aqueous solution of a ~eak.~ase ~.g~, sodium bicarbonatel until the aqueous layer i5 neutral Cfor the. a~ydride routel or is ~ash~ wit~
water Cfor th~. amide route.l. The organic layer i5 separated and any solvent present is removed to ohtain the respective intermediate amides CrVl, CrVAl, and CVl~
The intermediate. amide.lc treated either neat or in the prese~ce of an organic solvent such as, for example, a h~locarbon CCx~l3~ C ~ C12) or a hydrocar~on U~enzene, toluen~) at 25~ to 100C with a suitahle activating agent, 5 describ~d previously, for about t~o to three hours, to produce the activated derivative (.VI~, after which the reaction mixture is allowed to cool. Addition of the appropriate primary amine CVII~ yields the de-sired product of Formula ~I~ which may be isolated and purified by known methods dis~ussed above. Th.e above reaction scheme may be illustrated by the following, .Rl, R1, Rl, R2, R3, A, B, D, Z, and X are as originally defined:
v~
Rl'~ D
Il ~ A~_J ~c~tl~l~t~ng IV ~nt s~ D ~1 ~ D
R ~ tC113 ) 2 ~ ~ng Rl / ~ a ~7 ~ nt ~;N~ R3N112 SVA ~ VI
R ~1~,D ~ ctl~tlng r~lcyl~ 20 ~ r~~g~nt A~ lv.l r-lJcyl R ~ 1 V 7~ NR3 ~ hen Z is Uo~eralkyl~-S-~ the compounds of Formula CI2 wherein R2SH may also be obtained iy reacting the activated intermediate ~VI) with. the appropriate isocyanate of Formula (VIII), pre~erably at the reflux temperature of the solvent (e.g., toluene) for about nine days. This reac~ion scheme is illustrated by the following:
R B Rl 1~JL---L~D
1 ~ ~ lo~eralkyl A ~ N=C' H + R3N=C=0 ~ I~R2 VI VIII
Because the subject compounds CIl possess a basic amidine group, they may be converted into the corresponding acid addition salts.
The acid addition salts may be prepared by reaction with an appropriate acid, as for example an inorganic acid such as a hydrohalic acid, i~e , hydro-chloric, hydro~romic or hydriodic acid; sulfuric or nitric acid; phosphoric acid; an organic acid such.as acetic, propionic, glycolic, pamoic, pyruvic, oxalic, malonic, succinic, maleic, picric, fumaric, malic, tartaric, citric, ~enzoic, cinnamic, mandelic, methane-sulfonic, ethanesulfonic, benzenesulfonic, E~toluenesulfonic, salicylic, 2-naphthalenesulfonic or ~-aminosalicylic acid. The therapeutically active, non-toxic acid addi-tion salts of subject compounds (I) are included within the scope of the present invention.
The starting materials of Formulas ~II), ~III), (IV), (IV~), (V), (VI), (VII), and (VIII) are known or may be prepared by known methods. See generally R. C.
Elderfield, ~eterocyclic Compounds, Vol. 1, Ch. 9, pp 617-77 (1950). Preparative methods for compounds (II) are described in, for example, articles by F. Ravenna, Farmaco (Pavia) Ed. Sci., 14, 473-82 (1959) and E. Sury and R. Hoffman, Helv. Chim. Acta., 248, 2133 (1954).
Preparative methods for compounds (III) and (IV) are des-cribed in, for example, articles by R. Ohme and E. Schmitz, Angew. Chem Intern. Ed., 6, 566 (1967), F. Snydam, et al., J. Org. Chem., 34, 292 (1969), and R. Sechinger, Helv. Chim. Acta., 56, 776 (1973). Preparative methods for compounds (V) and (VI) are described in, for example, C. A. Buehler and D. E. Pearson, Sur~ey of Or~anic Syn-theses, Cho 18~ p 894 (1970).
Method of Testing The compounds of the invention are useful for inhibition of gastric acid secretion as measured by the following test. Female Sprague-Dawley rats are fasted twenty-four hours before testing and are given water ad libidum while being kept in individual cages. On the .
day of testing~ the rats are weighed and are selected 80 that the rats in each test weigh within a range of + 20 grams.
Surgery is carried out under light ether anesthesia. As soon as the rat is anesthetized its teeth are removed and a mid-line incision is made on the ab-domen about 1 1/2 inches in length and the stomach and duodenl~m are exposed. If at this point the stomach is filled with food or fecal material, the rat is discarded.
If the condition of the stomach is acceptable, a purse string stitch is placed on the fundic portion of the stomach with a suture, taking care not to pierce any blood vessels in the area. A small nick is then made ~14V~ ~l8 into the stomach in the center of the purse string, and a cannula, consisting of a small vinyl tube with a flange on one end, is put into the stomach, and the purse string stitch is closed tightly around the flange. The test compound is administered either i~b=YhIdona~ly ~d.l immediately-aft r surgery or orally (~.o~l one hcur prior bo surgery at doses gene~ally ranging from about 0.25 to about 160 mg/kg in a volume of 0.5 ml/100 grams rat. Control rats receive the-test vehicle, Q.5% aoueous methyl cellulose.
After the surgery and (in the case of i.d. ~d-ministration~ after administration of the test compound, the abdominal wall and skin are clo~ed simultaneously with three or four 18 mm wound clips and a collecting tube is placed on the cannula. Each rat is then placed in a box in which a longitudinal slit has been made to allow the cannula to hang freely and to allow the rat to move about unencumbered. After the rat has been allowed to stabilize for thirty minutes, the collection tube on the cannula is discarded and replaced with a clean tube to receive the gastric juice. Collections are made at one hour. At th~ end of the study, the cannula is removed and the rat is sacrificed.
The sample of gastric contents collected is drained into a centrifuge tube and centrifuged to pack down the sedLment. The volume is read and a 1 ml ali-quot of the sup~rnatant is put into a beaker containing 10 ml distilled water and is titrated to pH7 using 0.01 N sodium hydroxide. Results are determined for Volume, Titrata~le Acid and Total Acid Output, where Volume equals total ml of gastric juice minus sediment;
Titratable Acid (meq/l) equals amount of O.Ol N sodium hydroxide needed to titrate the acid to pH7; and Total Acid Output equals Titratable Acid times Volume. Results are reported as the ED50 dose (mg/kg required to produce an average of 50% inhibition in Total Acid Output versus controls in all the animals tested for a particular oom-pound) and as percent inhibition. The compound~ of the invention all demonstrate a significant inhibition both i.d. an~ p.o. at less than 80 mg/kg, with preferred com pounds having an ED50 ~ less than 20 mg/kg. In con-trast, the prior art N-iminomethylpiperidine demonstrates no inhibition whatsoever at a dose of 100 mg/kg ~ o. or at 80 mg/kg id.
It is well-known that excessive se~retion of gastric hydrochloric acid leads to unneeded peptic activi-ty and endangers the mucous lining of the stomach. The use of gastric antisecretory agents is thus desirable as an aid in the prevention and amelioration of distress occasioned by high concentrations of stomach acid.
Description of the Preferred Embodiments Preferred compounds of the invention are those of Formula (I) wherein:
Rl is a ~ember selected from the group consisting of phenyl; phenyl substituted with from one to three mem-bers each selected from the group consisting of loweralkyl, loweralkoxy, halo, and phenyl, provided that no more than one member is p~enyl; phenyl(Cl-C4)loweralkyl; phenyl-(Cl-C4)loweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy and halo; diphenyl-(Cl-C4)loweralkyl and diphenyl(Cl-C4)loweralkyl wherein at least on~ of said phenyls is substituted with from one to three members each selected from the group con-sisting of loweralkyl, loweralkoxy, halo, and phenyl, provided that no more than one member is phenyl;
R2 is a member selected from the group consisting of hydrogen and methyl;
R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenyl-loweralkyl in which said phenyl is substituted with from one to three members each selected from the group consis-ting of loweralkyl, loweralkoxy, and halo; alkenyl, and alkynyl; and Rl', Rl", A, B, and D are each hydrogen.
More preferred compounds of the invention are those of Formula ~I) wherein:
1~4~)~1t3 Rl is a member selected from the group consisting of diphenylmethyl and diphenylmethyl wherein at least one of said phenyls is substituted with from one to three m~hers each selected ~rom the group consisting of lower-alkyl, lowera~oxy, and halo;
R2 is hydrogen;
R3 is a member selected ~rom the group consistingof hydrogen; alkyl; phenylloweralkyl; phenylloweralkyl in which said phenyl i8 substituted with from Qne to three members each selected from the group consisting of lower-alkyl, loweralkoxy, and halo; alkenyl; and alkynyl; and Rl', Rl", A, B, and D are hydrogen.
Most preferred compounds of the invention are those of Formula (I) wherein Rl is a member selected from the group consisting of diphenylmethyl and diphenylmethyl wherein one of said phenyls is subs~itued in the ~
position with a mP~her selected from the group consisting of loweralkyl, loweralkoxy, and halo; R2 is hydrogen; R3 is a mem~er selected from ~he group consisting of hydrogen, straight chain alkyl, and phenylloweralkyl; and Rl', Rl"~
A, B, and D are all hydrogen.
Description of the Method of Treatment and Pharmaceutical Compositions In view of the antisecretory activity of the subject compounds, there is further provided herein a met~od of inhibiting gastric acid secretion which com-prises internally admini~tering to a gastric hyperacidic subject (man or animal) an effective gastric acid secretion inhibiting amount of a substituted N-iminomethylpiperidine of Formula tI~, in base or acid addition salt form, pref-erably in admixtur~ with a pharmaceutically acce~tabl~carrier. If an acid addition sa}t form is used, said salt must of couræe ~e pharmaceutically-acceptable and non-toxic. Pharmaceutical compositions comprising a su~ject compound (I~ are also considered a further aspect of thP
3s present invention.
To prepare the pharmaceutical compositions of the present invention, a substituted N-iminomethylpiperidine of Formula (I~ or an acid addition salt thereof is combined M~ 335 ll~Q1 .18 as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharma-ceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of prepara-tion desired for administration, e.g., oral or parenteral.In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations such as for example, suspensions, elixirs, and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubri-cants, binders, disintegrating agents, ~nd the like in a case of oral solid preparations, such as for example, powders, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutioal ~arriers are obviously employed.
If desired, tablets may be sugar coated or enteric coated by ~tandard techniques. For parenterals, the carrier will usually comprise sterile water, although other ingredients, for example, to aid solubility or for preservative pur-poses, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, and the like, ~rom about ten to about five hundred milligrams of the active ingredient, and prefer-ably from about fifteen to about two hundred fifty milli-grams.
The following examples are intended to illustrate but not to limit the scope of the present invention.
EXAMPLE I
4-Diphenylmethyl-l-iminomethylpiperidine ~ ~ ochloride hydrate A suspension of 27.39g (0.25 mole) of ethyl formimidate hydrochloride ~prepared by the method of Ohme, et al., Angew. Chem. ~ntl. Ed., 6, 566(1967)] and 52.71g (0.20 mole) of diphenyl-4-piperidylmethane in 80 ml of freshly-opened absolute ethanol was stirred mag-netically under a calcium chloride tube overnight. The suspension was filtered and diethylether was added to the filtrate. The filtrate was stripped to dryness and the resulting oil was crystallized from isopropanol. The solid was then suspended in boiling ethyl acetate to obtain a higher melting form. Two recrystallizations from ethanol-ether yielded pure 4-diphenylmethyl-1-Lminomethyl-piperidine hydrochloride hydrate; m.p. 220-221C.
EXAMPLE II
Following the procedure of Example I, but sub-stituting for the ethyl formimidate hydrochloride and diphenyl-4-piperidylmethane ~sed therein, equivalent amounts of the appropriate starting materials, there are prepared the following:
R ~
1 ~ NC=NR3 . Salt A ~ ~2 Rl 5alt A R2 R3 m.p~ (C?
~ip~P~y~ yl ~Cl H C2H5 ~ 271.5-277.5 a-(4-m~h~yniE~y1) fumarate H H H 1~9.5-192.5 b~l , ~-~,4-h~nyl)-a- HCl H H H 216 -218 hy~lr3~1 p~enyl HCl H H H 204 -205 benzyl ECl o H H H 199 -201.5 phenyl HCl C-CH3 H H 172 -175 a-U~on~E~ ~rate H H H 192.5-194.5 ~yl l8 EXAMPLE III
4-(DiphPnylmethyl)-l-N-ethyliminomethyl-pip~ridine oxalate hemihydrate A mixture of 8.00g (0.029 mole) of N-formyl-4-diphenylmethy~piperidine and 3.51g (2.67 ml, 0.029 mole~
of dimethylsulfate was heated on a steam bath for two hours to give a clear thick syrup. To this material was then added 1.38g (2.00 ml, 0.031 mole) of ethylamine in 15 ml of methylene chloride. The resulting solution was stirred for 1.5 hours at 25, stripped, slurried in ether, and treated with 28 ml of 3 N sodium hydroxide solution. The ethereal layer was dried over potassium carbonate, filtered through diatomaceous earth filter aid and evaporated to give 8.77g of yellow li~uid. Treat-ment of this material in isopropanol with 3.26g of oxalicacid dihydrate afforded 5.0g of white solid m.p. 165-175C. Recrystallization from isopropanol afforded pure 4-(diphenylmethyl)-1-N-ethyliminomethylpiperidine oxalate hemihydrate as a white solid; m.p. 185-187C.
EXAMPLE IV
Following the procedure of Example III, but substituting for the ~-formyl-4-diphenylme~hylpiperidine and ethylamine used therein, e~uivalent amounts of the appropriate starting materials, there are prepared the following:
R1 ~ NC=NR3 Salt \J R2 _ R2 ~ Salt m.p. (C) dipheny~ yl H -C~2C~=CX2 cycld~ane 179.5-181 ~amate n H i-p~l fumarate 175 -178 ~ H n-butyl " 193.5-195 H n-hexyl ~ 179 -181.5 n H _-hepkyl ~ 175 -178 H n~x~yI " 157 -159 " H t-octyl " 227 -229 " H n-nonyl " 142 -144.5 ~14V~
R2 R3 Salt m.p. ( diphenylmEthyl ~ nrdecyl succ~nate 106 -109 n H ~ 1 ~umarate 143 -145.5 ~dra~e ~ H l-~mantyl fumarate 275 -276 n ~ benzyl cy~lohexane 164.5-166.5 n H ~1 n 141 -144 n H ~ 1 2-nLç~ ene 222 -224 ~ul~anate n H ~ 1 n 110.5-112.5 a- (4-r~eY~D~npYenyl) H n-octyl (E)-2-butene- 154.5-156 b~l dioate 10a- (4-methy1pheny1) H n-octyl n 161 -163.5 diphenylmethyl H 4 m~thyltEnzyl pt5~ or3te 242 -244 n H phenyl 4-tDluene- 285 -286 sulfonate EXAMPLE IVA
A mixture of 4-[(4-methoxyphenyl)phenylmethyl]-l-[~octylimino)methyl]piperidine (1.9Og, 0.0045 mole) and 42 ml of 47-49~ hydrobromic acid was refluxed one hour, cooled, and the aqueous portion decanted from a thick oil. The oil was dissolved in methylene chloride, rendered neutral with a~ueous sodium bicar~onate, dried and evaporated. The residue, 4-[(4-hydroxyphenyl)-phenylmethyl]-l-[(octylLmino)methyl]piperidine was con-verted to its 2~naphthalenesulfonio acid salt, m.p.
177.5-180C.
XAMPLE V
4-(Diphenylmethyl)-l-[(octyl$mino)methyl]-Pi~eridine Fumarate Hvdrate ", , _ A ~olution of triethyl oxonium fluoroborate [prepared from 104.6g (0.737 mole) of boron trifluoride etherate and 56.04g ~47.37 ml, 0.606 mole) of epichloro-hydrin] was dissolved in 800 ml of anhydrous methylene chloride and the resulting solution treated with 81.0g (0.516 mole) of N-(n-octyl) formamide and stirred over-nigh~ at 25$. 4-Diphenylmethylpiperidine (130g, 0.518 mole) was added and the mixture was stirred for four hours. A small amount of white solid was filtered off, r~
the filtrate made basic with 3 N sodium hydroxide solu-tion, separated, dried over potassium carbonate and evaporated to a yellow oil. This material was dissolved in isopropanol and treated with 6~g of fumaric acid with warming. Addition of an equal volume of aceto~e followed by ether caused a solid to form affording two crops of material m.p. 152-157C. These were combined and re-crystallized from ethanol-water to give two crops of 4-~diphenylmethyl)-1-[~octylimino)methyl]piperidine fumarate hydrate: m.p. 157-159C.
EXAMPLE VI
. . .
4-(Diphenylmethyl)-l-pipe-r-idinecarbothioaldehyd-e A solution o~ 20.0g (0.08 mole) of 4-diphenyl-methylpiperidine, 14.2g (0.16 mole) of N,N-dimethylthio-formamide and 50 ml of toluene was refluxed for 12 hours, cooled, and washed with water. The organic layer was separated, dried and stripped to an oil which was treated with diethyl ether to give a solid. Recrystallization of this material afforded a white crystalline solid, 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, m.p. 152-154C.
EXAMPLE VII
. .
Following the above procedure, but substituting for 4-diphenylmethylpiperidine used therein, an equiva-lent amount of an appropriate piperidine, there are pre-pared the following: R ' Rl / \ S
A ~ NCH
/ , .
Rl A Rl' m p. (C) 9-fluorenyl H H 142 - 146 H H Ph2CH 115 - 120 -~ benzyhydrylidene------- H 131 - 134 diphenylhydroxymethyl H H 200 - 203 EXAMæLE VIII
4-(Diphenylmethyl) -1-N-(n-dodecyliminomethyl)piperidine fumarate 35A solution of 5.54g (0.019 mole) of 4-(diphenyl-methyl)-1-piperidinecarbothioaldehyde in 20 ml of ~l~V~ ~l8 lg chloroform was treated with 2.65g tl.l6 ml, 0.019 mole) of methyl iodide and refluxed for one hour. The result-ing solution was treated with 3.49g (0.019 mole) of n-dodecylamine, refluxed one and one half hours, cooled, treated with aqueous sodium hydroxide and the organic layer separated. After drying, evaporation yielded an oil which was converted to the fumarate to yield 4-(diphenylmethyl)-l-N-(n-dodecyliminomethyl)piperidine fumarate; m.p. 143-145.5C.
EXAMPLE IX
Following the above procedure, but substituting for the 4-(diphenylmethyl)-1-p$peridinecarbothioaldehyde and n-dodecylamine used therein, equivalent amounts of the appropriate starting.materials, there are prepared 15 the following: Rl' Rl ~\
A ~ NCH=NR3 A ~' R3 Salt ~ p. ~C) H H
di~Y~lmetbyl H ( ~ )8C=C- fumara~_ ~inter (CH2)~CH3 hydrate 131 -13S
diphenylmethyl H H ~ C-CH HCl 117 -1l9 9H-flu~rg-yl H H n-C8H17 HCl 174 -177 H H diphenyl- n-C8H17 ~m~rate (sin~Pr 68.5) methyl . hylrate 70 -72 -be1~*y~ryl~ H n-C8H17 te 167 -170 diphenylhy~x3ynethyl H H n-C8H17 f~ate (.s nter 145) H H diF ~ 1- H fu~rate 185.5-187.5 methyl EXAMPLE X
Alternate Preparative Routes Illustrated for 4-(Diphenylmethyl?-l-[(octylimino)methyl]Piperidine 1) A mixture of 2.90g (0.01 mole) of 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, 129g (0.01 mole) of n-octylamine, 0.60g (0.01 mole) of glacial acetic acid and 20 ml of toluene was heated with stirring at 60 for two days. The reaction mixture was made basic ~l~V~
and concentrated to give an oil which was identified as 4-(diphenylmethyl~-1-[(octylimino)methyl]piperidine by vapor phase chromatography.
. .
BACKGRO~ND o~ TEE INVENTION
.
Unsubstituted ~-iminomethylpiperidine is dis-closed in United States Patent No. 2,615,023, but said compound does not inhibit gastric acid secretion even at dose~ four times or greater than those at which the subject compounds are active. It has now surprisingly been discovered t~at certain substituted N-Lminomethyl-piperidines are effective inhibitors of gastric acid secretion.
SUMMARY OF THE INVENTION
Description of the Compounds~
The present invention comprises substituted N-iminomethylpiperidines of Formula ~
R
Rl >~ NC=NR3 . A ~ R2 (I) wherein:
Rl taken individually is a member selected from the group consisting of hydrogen; phenyl;
phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, h~X~ and halo; ~yl(Cl~C4tloweraIkyl; l-phenyl(C7-Cg)-loweralkyl; p~enyltCl-C4Sloweralkyl and l-phenyl(C7-C9~-loweralkyl in which said phenyl is substituted with from 114V~
one to three members each selected from the group con-sisting of loweralXyl, loweralkoxy, hydroxy, halo, and phenyl, ~rovided that no more than one member is phenyl;
diphenyl(Cl-C4~loweralkyl; diphenyl(Cl-C4)loweralkyl S wherein at least one of said phenyls is substituted with from one to three memhers each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is pheny}; diphenylhydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls i5 gubstituted with from one to three members each selected from the group consi~ting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
~C ~ and wherein n is 0, 1, or 2 and E is H or OH;
A t~ in~ivi~E~ly is a memker selected frcm the ~roup conslcting of ~x~en, acetyl, an~ phenyl, provided that when A is acetyl or phenyl, Rl i5 a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
Rl and A taXen together is a member selected ~rom the group consisting o~ benzhydrylidene and compounds of ~ormulae:
(C ~ and wherein n is 0, 1, or 2;
~ '~ individhally is a ms~ sel~ from the grDUD oonsi~ing of ~XX~n; methyl; diphenylmethy~; diphenyl--methyl wher~in at least one of the phenyl groups is sub-stituted with from one to three mem~ers each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenyl~
hydroxymethyl wherein at least one of said phenyls is su~stituted with from one to three members each selected from ~he group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member i~ phenyl; and a compound of formula:
~.
~C~
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen;
Rl' and B taken together is a member selected from the group consisting of ~enzhydrylidene and a compound of ~ormula:
(CH
wherein n i3 0, l, or 2.
Rl'taken individually is a m3mber sele~ fLal~the grou~ consistmg of hy~ , diphenylmet~yl; diphenylmethyl wherein at least one of said phenyls is substituted with frcm one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, pro-vided that no more than one m~oer is phenyl; diphenyl-hydroxymethyl; diphenylhydroxymethyl wherein at least ~40~ 18 one of sa~d phenyls is substituted with from one to three members each selected ~rom the group consisting of loweralkyl, loweralko~y, hydroxy, halo, and phenyl, provided that no more than one mernber is phenyl; and compounds of formulae:
~ H and ~ H
wherein n is 0, 1, or 2:
D taken individually is hydrogen;
Rl" and D taken together is benzhydrylidene.
R2 is a member selected from the group consisting of hydrogen and Cl-C4 loweralkyl; and R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenylloweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; diphenyl(Cl-C4)10weralkyl; di-phenyl(Cl-C4)loweralkyl in which at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl;
alkenyl; and alkynyl; provided that at least one of said Rl, R'l and R"l is other than hydrogen and further provided that when R"l is other than hydrogen Rl, and R'l, and A are each hydrogen; when R'l is hydrogen only one of Rl and R"l is other than hydrogen; when R'l is methyl Rl is other than hydrogen and R"l is hydrogen; and when R'l is other than hydrogen or ethyl Rl, R"l and A are each hydrogen.
As used herein~loweralkyl and loweralkoxy may be straight or branched chain saturated aliphatic hydrocarbons having from one to eight carbon atoms, such as for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, and the like lower-alkyls, and, respectively, the corresponding loweralkoxys, e.g., methoxy, r~ ~
1~L~V~.18 ethoxy, propoxy, isopropoxy, butoxy, pentoxy, and the liXe. The term "Cl-C4 loweralkyl" includes those lower-alkyls having from one to four carbon atoms, such as for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec butyl, and the like. The terms "phenyl-(Cl-C4)loweralkyl" and "diphenyl(Cl-C4)loweralkyl" include only those compounds where the phenyl group( 5 ) are bonded to the terminal carbon atom of a straight chain loweralkyl, such as 2-phenethyl, 4-phenylbutyl, 4,4-diphenylbutyl, 3,3-diphenylpropyl, and the like. The term n l-phenyl-(C7-Cg)loweralkyl" includes groups having the following general formula:
~1 (C~ 2)m c~3 where m is 5, 6,~r 7. me tenm "alkyl" includes straight or branched chain saturated aliphatic hydrocarbons having up to about sixteen carbon atoms, such as for example, the a~o~e mentioned loweralkyls and fsrther such radicals as hexyl, heptyl, octyl, nonyl, decyl, dodecyl, hexadecyl, and the like. The term "cycloalkyl" includes mono-, bi-, and tricyclic saturated and unsaturated aliphatic hydro-carbons having up to about ten carbon atoms, such as for example, cyclohexyl, adamantyl, l-adamantyl-methyl, exo-norbornyl, endo-norbornyl, noradamantyl, anti-7-norbornenyl, and the like. The terms "alkenyl" and "alkynyl" include straight and branched chain hydro-carbons having from two to about eighteen carbon atoms and at least one double or triple bond, respectively, such as for example, allyl, methallyl, l-propargyl (l-propynyl), 2-pentenyl, and the like. The term "halo"
includes fluoro, chloro, bromo and iodo.
Methods of Preparation The compounds of Formula I may generally be prepared by reacting together: a) an appropriately-6ubstituted piperidine of Formula (II) with an appropriate activated amide (Formula III), or b) an appropriate primary amine of Formula (VII) with an activated N-acyl ~Vt ~
piperidine of Formula (VI), said activation in either case having been achieved by treatment of the respective amide with a suitable activating agent selected from, for example, phosgene, Me30 BF4 , Et30 BF4 , (MeO)2S0 MeOS02F, POCl~, PC15 and the like.
Included in the terms n amide n and "N-acyl-piperidine" as used herein are the corresponding thio derivatives in which the carbonyl oxygen has been re-placed by sulfur. In the case of the thio derivatives, there are additional suitable activating agents which may be employed, such as for example, loweralkyl halides (methyl halide being preferred), methyl tosylate, methyl sulfonic acid esters te.g., methyl methanesulfonate) methyl trifluoromethylsulfonate, and the like.
The activated reactant o~ Formula (III) may be in either free base or acid addition salt form.
Specific preparative routes are given below:
~ ) The compounds of Formula (I) may be pre-pared by reacting the appropriately-substituted piperidine of Formula (IT) with an appropriate imidate ester of Formula (III). The methyl and ethyl esters are preferred.
The substituted piperidine and the imidate ester (which may be present in either free base or acid addition salt form, the latter being shown) are stirred together in a suitable oryanic solvent such as, for example, a halo-carbon (e.g., carbon tetrachloride, chloroform, 1,2-dichloroethane, and the like), a loweralkanol (e.g., methanol, ethanol, isopropanol, and the like), an aromatic hydrocar~on (e.g., benzene, xylene, toluene, and the like), dimethylsu~foxide, and the like. The temperature of the reaction is preferably from about 0 to about 25C, and in some cases may be carried out as high as 50C, but in any event the temperature of the reaction must not be high enough to decompose significant amounts of the imidate e~ter. The resulting product may be isolated and purified by techni~ues known in the art, e.g., by stripping off the solvent and recrystallizing the desired produet in the free base or acid addition salt form.
The above reaction ~cheme may be illustrated by the 1147~ 18 following~ wherein Al B, D, Rl, Rl', Rln, R2, and R3 are as previously defined, Z is selected from the group con-sisting of loweralkoxy (preferably methoxy and ethoxy), loweralkyl-S- (preferably methylthio), chloro, and C12(0)P0-, and X is a member selected from the group consisting o~ halid~, BF4, FS03, and CH30S03. Addi-tionally, when Z is loweral~yl-S-, X may also be a member selected from the group consisting of (4-methylphenyl)S03, CH3S03, and CF3S03.
Rl' B 1 Rl~ B Ri ~ D \~ ~ D
Rl ~ NH + ZC=NR3 HX 3 ~ NC2NR3 ~ III) tI) The compounds of Formula tI) wherein R2 is hydrogen may also be-prepared ~y an analogous route by substituting an appropriate compound of Formula (IIIA) or (IIIB) for the imidate ester of Formula (III). If the former is used, the resulting thiourea is then re-duced (e.g., with Raney nickel) to give the desired com-pound. If the latter is used, silver c~loride is em-ployed as catalyst. These reaction schemes are illus-trated by the following:
....
R ' B'`l R ~
A ~ NH + R3N'C=S ~--_~thiOurcl reduction)(I) (R
(II) (IIIA) ~ ..
R ' B'`l R~
A ~ NH + R3N-C cat~l~ti~ l ) (I) (R2=H) tII) (IIIB) M~ 335 1~4V~l~
B) The compounds of Formula (I) may also be prepared by reac~i~g a suitably-substi~uted piperidine of ~ormula (II) with acetic formic anhydride or N,N-diloweralkylthioformamide (for R2=H~ or a Cl-C4 loweralkyl anhydride ~for R2=Cl-C4 loweralkyl), the anhydride pre-ferably being present in excess. The piperidine and anhydride or thio~n~m~de are combined with cooling and æe allowed to stir for about 18 hours. The resulting reac-tion mixture, either dissolved in an organic solvent ~elected from t~e aforementioned halocarhon and alipha-tic hydrocarhon ~olvents or ~ithout the addition of solvent, is then treated ~lt~ an aqueous solution of a ~eak.~ase ~.g~, sodium bicarbonatel until the aqueous layer i5 neutral Cfor the. a~ydride routel or is ~ash~ wit~
water Cfor th~. amide route.l. The organic layer i5 separated and any solvent present is removed to ohtain the respective intermediate amides CrVl, CrVAl, and CVl~
The intermediate. amide.lc treated either neat or in the prese~ce of an organic solvent such as, for example, a h~locarbon CCx~l3~ C ~ C12) or a hydrocar~on U~enzene, toluen~) at 25~ to 100C with a suitahle activating agent, 5 describ~d previously, for about t~o to three hours, to produce the activated derivative (.VI~, after which the reaction mixture is allowed to cool. Addition of the appropriate primary amine CVII~ yields the de-sired product of Formula ~I~ which may be isolated and purified by known methods dis~ussed above. Th.e above reaction scheme may be illustrated by the following, .Rl, R1, Rl, R2, R3, A, B, D, Z, and X are as originally defined:
v~
Rl'~ D
Il ~ A~_J ~c~tl~l~t~ng IV ~nt s~ D ~1 ~ D
R ~ tC113 ) 2 ~ ~ng Rl / ~ a ~7 ~ nt ~;N~ R3N112 SVA ~ VI
R ~1~,D ~ ctl~tlng r~lcyl~ 20 ~ r~~g~nt A~ lv.l r-lJcyl R ~ 1 V 7~ NR3 ~ hen Z is Uo~eralkyl~-S-~ the compounds of Formula CI2 wherein R2SH may also be obtained iy reacting the activated intermediate ~VI) with. the appropriate isocyanate of Formula (VIII), pre~erably at the reflux temperature of the solvent (e.g., toluene) for about nine days. This reac~ion scheme is illustrated by the following:
R B Rl 1~JL---L~D
1 ~ ~ lo~eralkyl A ~ N=C' H + R3N=C=0 ~ I~R2 VI VIII
Because the subject compounds CIl possess a basic amidine group, they may be converted into the corresponding acid addition salts.
The acid addition salts may be prepared by reaction with an appropriate acid, as for example an inorganic acid such as a hydrohalic acid, i~e , hydro-chloric, hydro~romic or hydriodic acid; sulfuric or nitric acid; phosphoric acid; an organic acid such.as acetic, propionic, glycolic, pamoic, pyruvic, oxalic, malonic, succinic, maleic, picric, fumaric, malic, tartaric, citric, ~enzoic, cinnamic, mandelic, methane-sulfonic, ethanesulfonic, benzenesulfonic, E~toluenesulfonic, salicylic, 2-naphthalenesulfonic or ~-aminosalicylic acid. The therapeutically active, non-toxic acid addi-tion salts of subject compounds (I) are included within the scope of the present invention.
The starting materials of Formulas ~II), ~III), (IV), (IV~), (V), (VI), (VII), and (VIII) are known or may be prepared by known methods. See generally R. C.
Elderfield, ~eterocyclic Compounds, Vol. 1, Ch. 9, pp 617-77 (1950). Preparative methods for compounds (II) are described in, for example, articles by F. Ravenna, Farmaco (Pavia) Ed. Sci., 14, 473-82 (1959) and E. Sury and R. Hoffman, Helv. Chim. Acta., 248, 2133 (1954).
Preparative methods for compounds (III) and (IV) are des-cribed in, for example, articles by R. Ohme and E. Schmitz, Angew. Chem Intern. Ed., 6, 566 (1967), F. Snydam, et al., J. Org. Chem., 34, 292 (1969), and R. Sechinger, Helv. Chim. Acta., 56, 776 (1973). Preparative methods for compounds (V) and (VI) are described in, for example, C. A. Buehler and D. E. Pearson, Sur~ey of Or~anic Syn-theses, Cho 18~ p 894 (1970).
Method of Testing The compounds of the invention are useful for inhibition of gastric acid secretion as measured by the following test. Female Sprague-Dawley rats are fasted twenty-four hours before testing and are given water ad libidum while being kept in individual cages. On the .
day of testing~ the rats are weighed and are selected 80 that the rats in each test weigh within a range of + 20 grams.
Surgery is carried out under light ether anesthesia. As soon as the rat is anesthetized its teeth are removed and a mid-line incision is made on the ab-domen about 1 1/2 inches in length and the stomach and duodenl~m are exposed. If at this point the stomach is filled with food or fecal material, the rat is discarded.
If the condition of the stomach is acceptable, a purse string stitch is placed on the fundic portion of the stomach with a suture, taking care not to pierce any blood vessels in the area. A small nick is then made ~14V~ ~l8 into the stomach in the center of the purse string, and a cannula, consisting of a small vinyl tube with a flange on one end, is put into the stomach, and the purse string stitch is closed tightly around the flange. The test compound is administered either i~b=YhIdona~ly ~d.l immediately-aft r surgery or orally (~.o~l one hcur prior bo surgery at doses gene~ally ranging from about 0.25 to about 160 mg/kg in a volume of 0.5 ml/100 grams rat. Control rats receive the-test vehicle, Q.5% aoueous methyl cellulose.
After the surgery and (in the case of i.d. ~d-ministration~ after administration of the test compound, the abdominal wall and skin are clo~ed simultaneously with three or four 18 mm wound clips and a collecting tube is placed on the cannula. Each rat is then placed in a box in which a longitudinal slit has been made to allow the cannula to hang freely and to allow the rat to move about unencumbered. After the rat has been allowed to stabilize for thirty minutes, the collection tube on the cannula is discarded and replaced with a clean tube to receive the gastric juice. Collections are made at one hour. At th~ end of the study, the cannula is removed and the rat is sacrificed.
The sample of gastric contents collected is drained into a centrifuge tube and centrifuged to pack down the sedLment. The volume is read and a 1 ml ali-quot of the sup~rnatant is put into a beaker containing 10 ml distilled water and is titrated to pH7 using 0.01 N sodium hydroxide. Results are determined for Volume, Titrata~le Acid and Total Acid Output, where Volume equals total ml of gastric juice minus sediment;
Titratable Acid (meq/l) equals amount of O.Ol N sodium hydroxide needed to titrate the acid to pH7; and Total Acid Output equals Titratable Acid times Volume. Results are reported as the ED50 dose (mg/kg required to produce an average of 50% inhibition in Total Acid Output versus controls in all the animals tested for a particular oom-pound) and as percent inhibition. The compound~ of the invention all demonstrate a significant inhibition both i.d. an~ p.o. at less than 80 mg/kg, with preferred com pounds having an ED50 ~ less than 20 mg/kg. In con-trast, the prior art N-iminomethylpiperidine demonstrates no inhibition whatsoever at a dose of 100 mg/kg ~ o. or at 80 mg/kg id.
It is well-known that excessive se~retion of gastric hydrochloric acid leads to unneeded peptic activi-ty and endangers the mucous lining of the stomach. The use of gastric antisecretory agents is thus desirable as an aid in the prevention and amelioration of distress occasioned by high concentrations of stomach acid.
Description of the Preferred Embodiments Preferred compounds of the invention are those of Formula (I) wherein:
Rl is a ~ember selected from the group consisting of phenyl; phenyl substituted with from one to three mem-bers each selected from the group consisting of loweralkyl, loweralkoxy, halo, and phenyl, provided that no more than one member is p~enyl; phenyl(Cl-C4)loweralkyl; phenyl-(Cl-C4)loweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy and halo; diphenyl-(Cl-C4)loweralkyl and diphenyl(Cl-C4)loweralkyl wherein at least on~ of said phenyls is substituted with from one to three members each selected from the group con-sisting of loweralkyl, loweralkoxy, halo, and phenyl, provided that no more than one member is phenyl;
R2 is a member selected from the group consisting of hydrogen and methyl;
R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenyl-loweralkyl in which said phenyl is substituted with from one to three members each selected from the group consis-ting of loweralkyl, loweralkoxy, and halo; alkenyl, and alkynyl; and Rl', Rl", A, B, and D are each hydrogen.
More preferred compounds of the invention are those of Formula ~I) wherein:
1~4~)~1t3 Rl is a member selected from the group consisting of diphenylmethyl and diphenylmethyl wherein at least one of said phenyls is substituted with from one to three m~hers each selected ~rom the group consisting of lower-alkyl, lowera~oxy, and halo;
R2 is hydrogen;
R3 is a member selected ~rom the group consistingof hydrogen; alkyl; phenylloweralkyl; phenylloweralkyl in which said phenyl i8 substituted with from Qne to three members each selected from the group consisting of lower-alkyl, loweralkoxy, and halo; alkenyl; and alkynyl; and Rl', Rl", A, B, and D are hydrogen.
Most preferred compounds of the invention are those of Formula (I) wherein Rl is a member selected from the group consisting of diphenylmethyl and diphenylmethyl wherein one of said phenyls is subs~itued in the ~
position with a mP~her selected from the group consisting of loweralkyl, loweralkoxy, and halo; R2 is hydrogen; R3 is a mem~er selected from ~he group consisting of hydrogen, straight chain alkyl, and phenylloweralkyl; and Rl', Rl"~
A, B, and D are all hydrogen.
Description of the Method of Treatment and Pharmaceutical Compositions In view of the antisecretory activity of the subject compounds, there is further provided herein a met~od of inhibiting gastric acid secretion which com-prises internally admini~tering to a gastric hyperacidic subject (man or animal) an effective gastric acid secretion inhibiting amount of a substituted N-iminomethylpiperidine of Formula tI~, in base or acid addition salt form, pref-erably in admixtur~ with a pharmaceutically acce~tabl~carrier. If an acid addition sa}t form is used, said salt must of couræe ~e pharmaceutically-acceptable and non-toxic. Pharmaceutical compositions comprising a su~ject compound (I~ are also considered a further aspect of thP
3s present invention.
To prepare the pharmaceutical compositions of the present invention, a substituted N-iminomethylpiperidine of Formula (I~ or an acid addition salt thereof is combined M~ 335 ll~Q1 .18 as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharma-ceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of prepara-tion desired for administration, e.g., oral or parenteral.In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations such as for example, suspensions, elixirs, and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubri-cants, binders, disintegrating agents, ~nd the like in a case of oral solid preparations, such as for example, powders, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutioal ~arriers are obviously employed.
If desired, tablets may be sugar coated or enteric coated by ~tandard techniques. For parenterals, the carrier will usually comprise sterile water, although other ingredients, for example, to aid solubility or for preservative pur-poses, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, and the like, ~rom about ten to about five hundred milligrams of the active ingredient, and prefer-ably from about fifteen to about two hundred fifty milli-grams.
The following examples are intended to illustrate but not to limit the scope of the present invention.
EXAMPLE I
4-Diphenylmethyl-l-iminomethylpiperidine ~ ~ ochloride hydrate A suspension of 27.39g (0.25 mole) of ethyl formimidate hydrochloride ~prepared by the method of Ohme, et al., Angew. Chem. ~ntl. Ed., 6, 566(1967)] and 52.71g (0.20 mole) of diphenyl-4-piperidylmethane in 80 ml of freshly-opened absolute ethanol was stirred mag-netically under a calcium chloride tube overnight. The suspension was filtered and diethylether was added to the filtrate. The filtrate was stripped to dryness and the resulting oil was crystallized from isopropanol. The solid was then suspended in boiling ethyl acetate to obtain a higher melting form. Two recrystallizations from ethanol-ether yielded pure 4-diphenylmethyl-1-Lminomethyl-piperidine hydrochloride hydrate; m.p. 220-221C.
EXAMPLE II
Following the procedure of Example I, but sub-stituting for the ethyl formimidate hydrochloride and diphenyl-4-piperidylmethane ~sed therein, equivalent amounts of the appropriate starting materials, there are prepared the following:
R ~
1 ~ NC=NR3 . Salt A ~ ~2 Rl 5alt A R2 R3 m.p~ (C?
~ip~P~y~ yl ~Cl H C2H5 ~ 271.5-277.5 a-(4-m~h~yniE~y1) fumarate H H H 1~9.5-192.5 b~l , ~-~,4-h~nyl)-a- HCl H H H 216 -218 hy~lr3~1 p~enyl HCl H H H 204 -205 benzyl ECl o H H H 199 -201.5 phenyl HCl C-CH3 H H 172 -175 a-U~on~E~ ~rate H H H 192.5-194.5 ~yl l8 EXAMPLE III
4-(DiphPnylmethyl)-l-N-ethyliminomethyl-pip~ridine oxalate hemihydrate A mixture of 8.00g (0.029 mole) of N-formyl-4-diphenylmethy~piperidine and 3.51g (2.67 ml, 0.029 mole~
of dimethylsulfate was heated on a steam bath for two hours to give a clear thick syrup. To this material was then added 1.38g (2.00 ml, 0.031 mole) of ethylamine in 15 ml of methylene chloride. The resulting solution was stirred for 1.5 hours at 25, stripped, slurried in ether, and treated with 28 ml of 3 N sodium hydroxide solution. The ethereal layer was dried over potassium carbonate, filtered through diatomaceous earth filter aid and evaporated to give 8.77g of yellow li~uid. Treat-ment of this material in isopropanol with 3.26g of oxalicacid dihydrate afforded 5.0g of white solid m.p. 165-175C. Recrystallization from isopropanol afforded pure 4-(diphenylmethyl)-1-N-ethyliminomethylpiperidine oxalate hemihydrate as a white solid; m.p. 185-187C.
EXAMPLE IV
Following the procedure of Example III, but substituting for the ~-formyl-4-diphenylme~hylpiperidine and ethylamine used therein, e~uivalent amounts of the appropriate starting materials, there are prepared the following:
R1 ~ NC=NR3 Salt \J R2 _ R2 ~ Salt m.p. (C) dipheny~ yl H -C~2C~=CX2 cycld~ane 179.5-181 ~amate n H i-p~l fumarate 175 -178 ~ H n-butyl " 193.5-195 H n-hexyl ~ 179 -181.5 n H _-hepkyl ~ 175 -178 H n~x~yI " 157 -159 " H t-octyl " 227 -229 " H n-nonyl " 142 -144.5 ~14V~
R2 R3 Salt m.p. ( diphenylmEthyl ~ nrdecyl succ~nate 106 -109 n H ~ 1 ~umarate 143 -145.5 ~dra~e ~ H l-~mantyl fumarate 275 -276 n ~ benzyl cy~lohexane 164.5-166.5 n H ~1 n 141 -144 n H ~ 1 2-nLç~ ene 222 -224 ~ul~anate n H ~ 1 n 110.5-112.5 a- (4-r~eY~D~npYenyl) H n-octyl (E)-2-butene- 154.5-156 b~l dioate 10a- (4-methy1pheny1) H n-octyl n 161 -163.5 diphenylmethyl H 4 m~thyltEnzyl pt5~ or3te 242 -244 n H phenyl 4-tDluene- 285 -286 sulfonate EXAMPLE IVA
A mixture of 4-[(4-methoxyphenyl)phenylmethyl]-l-[~octylimino)methyl]piperidine (1.9Og, 0.0045 mole) and 42 ml of 47-49~ hydrobromic acid was refluxed one hour, cooled, and the aqueous portion decanted from a thick oil. The oil was dissolved in methylene chloride, rendered neutral with a~ueous sodium bicar~onate, dried and evaporated. The residue, 4-[(4-hydroxyphenyl)-phenylmethyl]-l-[(octylLmino)methyl]piperidine was con-verted to its 2~naphthalenesulfonio acid salt, m.p.
177.5-180C.
XAMPLE V
4-(Diphenylmethyl)-l-[(octyl$mino)methyl]-Pi~eridine Fumarate Hvdrate ", , _ A ~olution of triethyl oxonium fluoroborate [prepared from 104.6g (0.737 mole) of boron trifluoride etherate and 56.04g ~47.37 ml, 0.606 mole) of epichloro-hydrin] was dissolved in 800 ml of anhydrous methylene chloride and the resulting solution treated with 81.0g (0.516 mole) of N-(n-octyl) formamide and stirred over-nigh~ at 25$. 4-Diphenylmethylpiperidine (130g, 0.518 mole) was added and the mixture was stirred for four hours. A small amount of white solid was filtered off, r~
the filtrate made basic with 3 N sodium hydroxide solu-tion, separated, dried over potassium carbonate and evaporated to a yellow oil. This material was dissolved in isopropanol and treated with 6~g of fumaric acid with warming. Addition of an equal volume of aceto~e followed by ether caused a solid to form affording two crops of material m.p. 152-157C. These were combined and re-crystallized from ethanol-water to give two crops of 4-~diphenylmethyl)-1-[~octylimino)methyl]piperidine fumarate hydrate: m.p. 157-159C.
EXAMPLE VI
. . .
4-(Diphenylmethyl)-l-pipe-r-idinecarbothioaldehyd-e A solution o~ 20.0g (0.08 mole) of 4-diphenyl-methylpiperidine, 14.2g (0.16 mole) of N,N-dimethylthio-formamide and 50 ml of toluene was refluxed for 12 hours, cooled, and washed with water. The organic layer was separated, dried and stripped to an oil which was treated with diethyl ether to give a solid. Recrystallization of this material afforded a white crystalline solid, 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, m.p. 152-154C.
EXAMPLE VII
. .
Following the above procedure, but substituting for 4-diphenylmethylpiperidine used therein, an equiva-lent amount of an appropriate piperidine, there are pre-pared the following: R ' Rl / \ S
A ~ NCH
/ , .
Rl A Rl' m p. (C) 9-fluorenyl H H 142 - 146 H H Ph2CH 115 - 120 -~ benzyhydrylidene------- H 131 - 134 diphenylhydroxymethyl H H 200 - 203 EXAMæLE VIII
4-(Diphenylmethyl) -1-N-(n-dodecyliminomethyl)piperidine fumarate 35A solution of 5.54g (0.019 mole) of 4-(diphenyl-methyl)-1-piperidinecarbothioaldehyde in 20 ml of ~l~V~ ~l8 lg chloroform was treated with 2.65g tl.l6 ml, 0.019 mole) of methyl iodide and refluxed for one hour. The result-ing solution was treated with 3.49g (0.019 mole) of n-dodecylamine, refluxed one and one half hours, cooled, treated with aqueous sodium hydroxide and the organic layer separated. After drying, evaporation yielded an oil which was converted to the fumarate to yield 4-(diphenylmethyl)-l-N-(n-dodecyliminomethyl)piperidine fumarate; m.p. 143-145.5C.
EXAMPLE IX
Following the above procedure, but substituting for the 4-(diphenylmethyl)-1-p$peridinecarbothioaldehyde and n-dodecylamine used therein, equivalent amounts of the appropriate starting.materials, there are prepared 15 the following: Rl' Rl ~\
A ~ NCH=NR3 A ~' R3 Salt ~ p. ~C) H H
di~Y~lmetbyl H ( ~ )8C=C- fumara~_ ~inter (CH2)~CH3 hydrate 131 -13S
diphenylmethyl H H ~ C-CH HCl 117 -1l9 9H-flu~rg-yl H H n-C8H17 HCl 174 -177 H H diphenyl- n-C8H17 ~m~rate (sin~Pr 68.5) methyl . hylrate 70 -72 -be1~*y~ryl~ H n-C8H17 te 167 -170 diphenylhy~x3ynethyl H H n-C8H17 f~ate (.s nter 145) H H diF ~ 1- H fu~rate 185.5-187.5 methyl EXAMPLE X
Alternate Preparative Routes Illustrated for 4-(Diphenylmethyl?-l-[(octylimino)methyl]Piperidine 1) A mixture of 2.90g (0.01 mole) of 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, 129g (0.01 mole) of n-octylamine, 0.60g (0.01 mole) of glacial acetic acid and 20 ml of toluene was heated with stirring at 60 for two days. The reaction mixture was made basic ~l~V~
and concentrated to give an oil which was identified as 4-(diphenylmethyl~-1-[(octylimino)methyl]piperidine by vapor phase chromatography.
2) A mixture of 2.0g (0.0068 mole) of 4-(di-phenylmethyl)-l-piperidinecar~othioaldehyde, O.9g (0.0069 mole) of n-octylamine, 2.16g (0.010 mole) of mercuric oxide and 15 ml of isopropanol was refluxed overnight, filtered and concentrated. The residue was treated with fumaric acid to give 4-(diphenylmethyl)-1-[(octylimino)methyl3piperidine (E)-2-butenedioate (1:1) hydrate which was identified by comparison with an authentic sample by thin layer chromatography.
3) A solution of l.Og (0.0034 mole) of 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, 0.59g (0.0038 mole) of n-octyl isocyanate and 6 ml toluene were refluxed nine days. Vapor phase chromatography in conjunction with mass spectral analysis showed
4-(dipheny}methyl)-1-[(octylimino)methyl]piperidine in the amount of 17% in the reaction mixture.
4) A solution of l.Og (0.0034 mole), of 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, 0.45g (0.0034 mole) of n-octylamine, and 6.0 ml isopropanol was refluxed overnight. Vapor phase chromatography analysis of the reaction mixture showed 4-(diphenylmethyl)-l-[(ootylimino)methyl]piperidine to be present.
4) A solution of l.Og (0.0034 mole), of 4-(di-phenylmethyl)-l-piperidinecarbothioaldehyde, 0.45g (0.0034 mole) of n-octylamine, and 6.0 ml isopropanol was refluxed overnight. Vapor phase chromatography analysis of the reaction mixture showed 4-(diphenylmethyl)-l-[(ootylimino)methyl]piperidine to be present.
5) A solution of 6.0g (0.035 mole) of n-octyl-isothiocyanate was dissolved in 25 ml of toluene, treated with 8.80g (0.035 mole) of 4-diphenylmethylpiperidine and stirred at 25 for twelve hours. The mixture was cooled, filtered and evaporated. Chromatography of the residue through silic~ gel using chloroform as an eluent aforded a brown oil, 4-(diphenylmethyl)-N-octyl-l-piperidinecarbothioamide. A mixture of l.Og (0.0024 mole~
of this material, 3g of Raney Nickel and 15 ml of iso-propanol was refluxed three hours, cooled, and filtered.Evaporation of the filtrate afforded an oil which was converted to a fumarate identified as 4-(diphenylmethyl)-l-[(octylimino)methyl]piperidine (E)-2-butenedioate (1:1) hydrate by thin layer chromatography.
of this material, 3g of Raney Nickel and 15 ml of iso-propanol was refluxed three hours, cooled, and filtered.Evaporation of the filtrate afforded an oil which was converted to a fumarate identified as 4-(diphenylmethyl)-l-[(octylimino)methyl]piperidine (E)-2-butenedioate (1:1) hydrate by thin layer chromatography.
6) A solution of N-formyl-4-diphenylmethyl-piperidine 40.0g (0.143 mole) and 50 ml of methylene chloride was treated with pho~gene until gas evolution ceased. After refluxing for one hour, the excess phosgene was removed under reduced pressure, the reaction was diluted with 50 ml of methylene chloride and ~4~8 ml (0.145 mole) of n-octyl amine in 25 ml of methylene chloride was introduced at such a rate as to maintain mild reflux. ~riethyl amine (28 ml) was added 510wly, the reaction stirred for ten minutes, and then poured into water. The organic phase was separated, washed with 20% sodium hydroxide solution, dried, and stripped to an oil which was converted to 4-(diphenylmethyl)-1-[(octyl-imino)methyl]piperidine (E)-2-butenedioate (1:1) hydrate, identified by thin layer chromatography.
7) A mixture of 5.60g (0.022 mole) of 4-di-phenylmethylpiperidine, 3.50g (0.022 mole) of n-octyl~
isonitrile, 0.26g (0.002 mole) of silver chloride, and 10 ml of toluene was stirred 48 hours at 25, filtered, stripped, and the residue dissolved i~ methylene chloride.
Extraction with 10% sodium hydroxide, drying and filtra-tion of the organic layer followed by evaporation afforded 4-(diphenylmethyl) l-[(octylimino)methyl]piperidine isolated as the fumarate salt, which was identified by thin layer chromatography.
EXAMPLE XI
Following the test procedure previously des-cribed, the following compounds were tested for their antisecretory activity. The ED50 values for p.o.
administration and the percent inhibition for i.d.
administration at 20 mg/kg are tabulated below (Ri =
H except where noted):
~1 R~ R2 A~NC=NR3 . _ . . ... , _ _ _ .. _ . . , .. _ . . ~
MN
~4~ ~8 O O O O ~O O ~D ~ ~ ~ ~ a~ c o ~o o o ~ In ~
~ O O O O O 0~ G 0 t~ ~ t~ O O ~ t` ~0 o 8 '` ~ ~ co ~ .` 'D ~ ~D ~ o ~ ~ ~
u~ C ~r o o ~ CD CO ~ ~ u~ ~ CO ~ ~` ~O ~ ~ O O O
k~ ~ ~ A V
~N ~J
1 ~ t ~ I r : ~ e .
~3' r~
l.8 ~3 a ~
o ~ O N t` C~ W 0~ ~
o o In ~ co I o ~ +~+U- ~
~I cl ~14V~ ~8 2~
EXA~?LE XII
Following the procadure described by Buehler and Pearson [Survey of Organic Syntheses, Ch. 18, p 894 (1970)] and using the appropriate substituted piperidine and anhydride, there are prepared the following piperidine S amides, wherein the following substituents are in the two (Rln), three ~Rl') or four ~Rl) position:
1~ Rl" , 1 ~ .NC=O
A ~ R2 Position of Substituent S~i~t ~ A
dipbeny~ yl 4 H H
c~ (4~11t~he~1)bq~1 n n n (4~rethylEiher~1) b~l n ~ n (4~1~9/~l)be~l n n n ct~ (4--chl~phe~l)}~l 3 9--fluor~l ~ n n d~hes~l n ~ n ph~yl 4 n phe~l n 4 ~ lar ~ yl " " H
4-chl~rcpheny~ " " phenyl 20 4-methcxypheny1 " " H
4-methcxyph~nyl " " phenyl 4-chlordbenzyl n n H
phenyl " methylphenyl pbenyl n n-butyL phenyl 25 o!(l,4-bipbenyl)benzyl " H H
or(l~4-biphenyl)b#nzyl " methyl o-(1,4-bipbenyl)henzyl " n-butyl n 2,2-dipheny1ethy1 " H "
2,2-diphenylethyl n methyl 30 2,2-diphenylethy1 ~ n-butyl "
10,11-cbhydrc-SH-dikenzo[a,d]-cycloheptene-S-yl 2 H "
~4V~
25 ~ositic~n of Su~tih~t Substituent ~ A
10,11~ ~5H~Z Ea~d] -qk~hept~5-yl 2 ræt~yl H
n n rs--~l~l n n- 4 H "
n " meff~yl n n--but 4,4~1-n-}~1 4 H ~
4 ~ 4~1~ l n T~l n 4 ~ 4~ l nn--butyl n 4~th~1 n H ~
benzyl - - n 9--f Lu~l n n n dip~3met~1ene n n -~-(4~1)~1 " " "
--(4~1p~yl)bOE~ n ~~ (4~1) be~ tl n n n dipe~l 3~ " "
Y~Y1 2 0 a--(4~hl~1) b~l n n n pheryl 4 n n 9--fluore~l n n n 4--chlxo~ - n 4~1 n n ~
2 5 4~c~1zyl n 1~ n 4~e~1 1~
~zyl .. .. ..
dipher~ylmethylene n n n a-(4~orc~yl)b~zyl " " "
(4~ctl~1) b~zyl ~' n ~
- (4~ret~1F~yl) b~zyl " " "
diE~henylme~yl 3 " "
9-flu~renyl 1. " "
~lw~l 4 " "
--(4--chlor~yl~b~zy1 3 n Positic~ of Substitu~t S~ entR~ A
5~o[a,d]cyc~5-yl 2 H H
n n me~l n n n--bu~yl lO,ll~ydro ~a,d] ~yc~5-yl n E~ n " " me~l "
n n n~ 5~1 n E~Tl (oc~l)mEt~l 4 H n n ~ yl n " n-h~l phe~l ~h~l)m~l ~ H
n }~1 n n n ~b~l n p~e~l n n n W~l n ~ n 4-ræ~1 n 1~ n be~l n n n Wllc~l ~I n n 4~ _1 n n n q~l 2 H n diE~yl n ~1 di~ lmethyl n n-butyl 5H~szota,d]cycloh~J~s-~-yl 4 H n 5~-d~#~c[a,d]cyclohq~5-yl n methYl n 5~d~x~o[a,d~cycJ~ en-5-yl " n-butyl EXAMPLE XIII
Following the procedure described by Buehler and Pearson [Survey of Organic Syntheses, Ch. 18, p 894 (1970)] and using the appropriate substituted piperidine and anhydride, there are prepared the following piperidine amides:
,~, s~
2)n Po~ition of Substituent n R2 n n CH3 S n n n--butyl " 1 H
n ~ CH3 n n n-butyl " 2 H
n n CH3 n 1l n-butyl-n n CH3 " " n-butyl " 1 H
n n CH3 n ~ n-butyl " 2 H
" " CH3 2 0 n n n-butyl 1~4~
EXAMPLE XIV
Following the procedure of Example XIII, there are prepared the following piperidine amides:
~,, ~ NC=O
wherein R2 = hydrogen, methyl~ or n-butyl.
EXAMPLE XV
Foll~wing the procedure of Example XIII, there are prepared the following piperidine amides:
(C6HS)2C ~\
~`NC80 10Position of Substituent R2 " CH3 " n-butyl n CH3 n n-butyl " CH3 n n-butyl 1~4~.8 EXAMPLE XVI
Following procedures describPd in the references given above for compounds o~ Formula ~III), the following are prepared: 1l IH
~2 R3 H -(CH2)llCH3 (CH2)7CH3 H -(CH2)l4CH3 H -(CH2~4CH-CHCH CH
Hcls-(cH2)5cH=cH(cH2)locH3 ( 2)6C_CH
H 4-ClPh-H 4-MeOPh-H 4-MePh-H -C~2C--CH
~ exo-2-norbornyl H endo-2-norbornyl Hl-decahydronaphthyl H l-adamantyl H2-bicyclo[2.2.2]octyl Hanti-7-norbornenyl Hendo-bicyclo[3.2.lloctyl Hl-adamantylmethyl Me H
Me -C2H5 Me -(CH2)5CH3 Me -(CH2)7CH3 Me -(CH2)l4CH3 Me-(CH2)4CH=CHCH2cH3 Meclg-(CH2)5CH=CH(CH2)loCH3 Me -CH~C-CH
Me (CH2)6C--CH
Me Ph Me 4-ClPh-Me 4-MeOPh-Me 4-MePh-Me PhCH2-Me 4-ClPhCH2-Me 4-MePhCH2-M~ 335 ~4(~
Me 4-MeOPhC~2-Me 2CH2 Me exo-2-norbornyl M~ endo-2-norbornyl Me l-decahydronaphthyl ~e l-adamantyl Me 2-bicyclo[2.2.2]octyl Me anti-7-norbornenyl Me endo-bicyclol3.2.1]octyl Me 1-adamantylmethyl n-Butyl H
l-nBU" ) Bu C2H5 Bu -CH2CH=CH2 Bu (CH2)7CH3 Bu (CH2)14CH3 Bu -(CH2)4CH=C~C2~5 Bu cis-(cH2)5C~=CH(cH2)locH3 Bu CH2C-CH
Bu ( 2)6C-H
Bu 4-ClPh Bu 4-MeOPh Bu 4-MePh Bu Ph Bu PhCH2 Bu 4-ClPhCH2-Bu 4-MePhCH2-~u 4-MeOPhCH2-Bu PhCH2CH2 ~u exo-2-norbornyl Bu endo-2-norbornyl Bu l-decahydronaphthyl Bu l-adamantyl Bu . 2-bicyclo[2.2.2]octyl Bu anti-7-norbornenyl Bu endo-bicyclo[3.2.1]octyl Bu l-adamantylmethyl H diphenylmethyl Me diphenylmethyl Bu diphenylmethyl H 3,3-diphenyl-n-propyl Me 3,3-diphenyl-n-propyl Bu 3,3-diphenyl-n-propyl ~40~ 18 EXAMPLE XVII
Following the procedure of either Example I or Example III, bu~ substituting for the ethyl formimidate hydrochloride and diphenyl-4-piperidylmethane or N-formyl-4-diphenylmetXylpiperidine and ethylamine, respectively, used therein, equivalent amounts of the appropriate starting materials such as described in Examples XII and XVI, there are prepared the following, wherein the following su~sti~uents are in the two (Rln), three (Rl'), or four (Rl) positions:
Rl l Rl n Rl ~<
A--\_~NC=NR3 Posi--tion of S~x*itNent S~x~i-~ ', or ~n) uent ~ R3 A
d~nylmethyl 2 H H H
dipheny~ yl 3 n ~ n 15 9-fluorenyl " n n n c~--(4~1)berlz~1 n n n "
di~ f~Nymethyl 4 " " n 10,11-dihy~x~5~ ~zo "
[a,d]cycloh~en-5-yl 4--chlon~x~y1 n n 20 4~o~enyl dipheny~E~l n n (~)11CH3 4~hlD~l n a-(4-methylphenyl)benzyl " " " "
4-chlorokenzyl n n n ~--(4~hl~1)--tY-- l~ n ~ydm~1 a-(4-~ophenyl)ben2yl 3 " " "
9-fluorenyl ~ n 4-metbI~uy1 4 " -(CH2)7CH3 9-~luorenyl 3 " n dipbenyl~y~s~ymethyl 2 a-(4~o~pY~y1)benzyl 3 " n 1~4V~
Posi--~ o n ) uent R2 R3 A
diph~nylhy~raxy~yl 4 H - (CH2) 7CH3 H
51~dikG~o[a,d3 n ~yc~hep~-5-yl yl n d~l (CH2) 14CH3 ~1 cr ~4--chlon~pherlyl ) b~lzyl 3 " " n 9-flu~renyl 4 " " "
~ 14-methyl~henyl)benzy1 "
4~hloq:c~1 n n n n ~1 " l~ ,. "
di~henylmet~yl " -(CH2)4C~I2CH3 ~E~l)benzyl n d~l8~t~1 3 10~11~5~ y_ ~
5}~dil~lzo [a,d] cyt:ld~5-yl 9--fll~lyl n ~ n di~ly~ret~lyl 4 ph~yl " " " "
~ ~l n ~ n diphenyl~ thyl n ~ CLs--(CEI2) cE~(CH2)10CH3 c~~ (4~hla~?he~1)b~zyl 3 9-~9-flUDl~T1 4 --(4~hl~lyl) ~~ I- ~ n n ~1 4~et~:yl " " " "
2 5 berlzyl ll ll ll n cr (4~1~ yl)be~1 n dip~Iylmethyl n " (CH2) 6C{~
a- (4-chlor~pbenyl) benzyl " " " "
~1 3 0 9-fluar~nyl 3 " " "
a-(4-chlorop~enyl)benzyl " " " "
dip~ylTrethyl 2 .. " n Posi--~ o S~nt S~
, R~ ', or Rln) uent ~2 .R3 A
}~1 4 H (C~z) 6C-CH . H
4--~leth~l n " n n d~T~ E~l n n --CH2C ~{ H n a--(4--leti~l)b~l n n a--(4~tly1p~1) ~-- n ~ n n ~1 --(4~L)berlzyl 3 " n n 9--fll~l 4 n n n [a,d] ~c1~5-y1 10 4~ethNyE~h~l n n n E~yl 4~hlo~c~1 n ~ n H
dipb~ n n exc~--2~1y1 n a- (4~et~y1p~1) b~1 " " ~ n a--(4~1)--a-- n n n n ~1 diF~lmet~l 3 n n n 9--flu~l ,. n E~yl 4 " n n 4-chLor~ibenzyl n n ~ n ~-(4~hlar~yl)b~zy1 " " en~2-nor~ornyl "
diphe~ethyl " n n di~enyl~ ~ethyl a-(4-chlorop}~yl)benzyl 3 9--flu~l ~ .. n n 4~y~yl 4 " " "
b~zyl ~ .. "
di~enylIrethyl ~ nl--deca~ydr~phthyl n a- (4~yl) b~zyl " n ~- (4-methylp~yl)--a- n ~b~l dipheny~thyl 3 "
9--fluorenyl ~ .- n ~
p~enyl 4 " " "
4-chlor~l ~- (4-meth~yl)benzyl " " l~nantyl "
~14 Posi-tian o~
Sl~bstituent Su~
(Rl, Rl', ar Rln) uent R2 R3 A
10 ,11--di3y~5-~dr~ 4 H1-ad~nan~yl H
5}}di~ ta,drc~yc~5-yl ~~ (4~hlo~l)_a_ n n ~ n ~1 a--(4~1)b0zy1 3 n n 9--flg~l n ~-4--chl~l 4 n n F~l n n n El diph~et~l n n2-bic~yclo~2.2.2]oc~1 -(4-~retl~1)~enzy1 " " " "
d~ ~Crc~l " n n n diphen~l 3 n n n 9--fluore~l 4 n n E~l .. n n 4~etho~1 ~ n n n 15 dip} ~ ~rethS~l n a ~ -7-I
-~4-c~lk=~ enyl)benzyl " n n ~-(4 m~Lhylphenyl)-~- n n ~1 dipheny~mEthyl 3 n n -9-fluorenyl " " " "
20 phenyl 4 n n 4-~hlorobenzy1 " " " "
diphenylmethyl " " enlo-bicy~10[3.2.1]octyl o-(4-methylpheny1)benzy1 " " n n diphenyIhydroxy=ethyl n n n ~
25 ~-(4-chlorcpbeny1)benzyl 3 " " "
9-fluorenyl n n dipbenyIhydr=xymethyl 2 " " "
4-methcxypbenyl 4 " " "
b ~ zyl " n n 30 diphenylmethyl " "l-adamantylmethyl "
-(4-methcxyph~=yl)benzyl " " n n a-(4-chlo ~ 1)_o_ n n hydrax ~ l a-(4-chlorc~henyl)benzyl 3 V~ ~ ~
Posi--tion o 9-flu~l , 3 Hl-adamantyl~1 H
phe~l 4 n ~ . n 4--sw~l n ~ n n diE~3~1m~1 laeth~l H n --(4~1)~1 n n ~ n a--(4--chl~Yl)~~ n n n n ~1 5--~51~di~1zo n n n n [a,d] c:ycl~-5-yl ~ (4~yl)ber~ 1 3 ~ n 9--fluorer~1 n n n diEhel~lmeff~l 2 n n ~
4--chlcl~l 4 n n 1 be~l n n 11 n t~ (4--llethc~phe~l)be~l ~I n n n a--(4~ylpt~nyl)--a-- n n ~ n ~1 dip~yl~ }~l 3 n 1~ n 9--h~r~9--flua~l 4 n n ~
4~th~y~yl " " " "
2 0 10 ,11 di~yd~5i}di~eDzo [a,d] cycl~-5-yl b~lzyl ~- n (~(4~1phe~lyl)be~lzyl n --(CH2)7CH
dipher~llyd~ynet~yl n a- (4~hlo~1)~1 3 n 2 5 9--fluor~l p}~l 4 " " "
be2~zyl ~ n n dipheny~nethyl " "(~ H2) 14CH3 a- (4~hl~phen~1)benzy1 " " "
3 0 a- (4~ret~y1) ~ " "
hydm~yl dipherlyln~l 3 " " "
9-fluoren~l " " "
Posi ti~l of o~ Rln)uent R2 R3 4~etlcyphenyl, 4 I~etl~l(CH2) 14CH~ H
4--chlorobenzyl " n n n d:i~y~hyl " n--CH2CE~=CH2 n a--(4--~l~ti~l)b~ln n n n l n r n Eh ~1 n n ~ H
a-~4~1)bq!1 3 " " n 9--flu~re~yl n n Il n 4--chlor~henyl 4 bq~l " " " "
dipe~lllet~l n n~ (CH2 ) 4CE~H2CH3 a--(4~ethylphe~1)be~1 n n n n a--(.4~bl~Y1)~-- n u n n ~1 di.E~ylIIethyl 3 n n n 9~fluorenyl l 4 n n n 4-chlorobenzyl " ~ n n diphenylmeth yl ~- n Cis--(CH2~5C~=CH( ~ )10 3 a-(4-methDxyphenyl~ken2yl" " " n diphenYlhydroxymethyl " " " "
g-flu~renyl 3 n a-~4-chl~opheny1)benzyl " " n 4--me~/l 4 ~ n 25 b~lzyl ll 1' ~I ll a--(4-methylphenyl)benzyl n l~ n a-(4-chlorcphenyl)-a_ " "
}~1 phenYlmethyl 3 " n ll 30 g-hydroxy-9-fluorenyl 4 " " "
~yl "
4-metho~ybenzy1 dipbenylmethyl n n~ (CH2) 6C---CH n a-(4-chlorophenyl)benzyl " " n diphenyIhy~roYymet~yl " " " "
l8 Posi-tion of S~b~t S~
(R~., Rl', or Rl") uent ~ R3 A
dip~y~e~l 3 nE~yl--(CH2)6C~CH H
9--f luorer~l n n n n diFbe~lly~3~1e~1 2 " n n 4~hlc3~ 4 ~ n diphe~l~E*}~l n n benzyl n a-(4~p~1)benzy1 " " 4-chlc~e~1 "
diphe~Tlh~ 4~
diEihe~y~l 3 " 4~1b~1 "
10 ~ dih~5--~n n n n 5}}dib~zo [a,d3 c:yc1at~5-yl 9--fluor~Tl - n "
-(4~yp~1)~enzyl 4 " 4~ora}~nzyl "
4--chlor~benzyl " ' benzyl n diph~ny~ yl " " ~2~ ornyl n a--~4~eth~1pbenyl) b~zyl n 1- n n ~Iyl ~ n n p~ enyl diphe~ynet~l n ~ n H
diph~nylmRthyl 3 2 0 Eiber~l 4 n n 9--fluorenyl 3 ~. n ~1 4 ~ n 10,~ ydr~5E~dib~zo [a,d] c~clo~p~-~yl dip~ny~rethyl ~ " ~2-n~ornyl "
a-(4 chlorc~henyl)benzyl " " " "
--(4~net~1ph~nyl)~- n n n h~dra~l diF~y~rethyl 3 " " "
9--fluorenyl n n n n 4~reth~p~enyl 4 " " n 3 o 4~or~zy1 " " " "
dip~yl~thyl " " l--decalyd~p~thyl n - (4-~y~l)benzyl " " " "
dip~y~t~l " " "
-(4 chl~1)benzyl 3 " " "
~ 335 1~4~
Posi-ti~ of Substituent Sl~bSti-(Rl, Rl', or RLn) uent R2 R3 A
4~hlQ~yl 4 n n n 4--net~yb~1 n n n n 5di~lmet~l n n1 a~~
~- (4~hlom~y1~benzy1 n ~ n n --(4t~ n n ll n h~drax~l dip~ylIl~l 3 n n n 9--flu~r~yl " " n n E~l 4 " " "
benzyl diphe~et~l n n2--bi~yclo[2.2.2]oc~yl "
dip~Dydr~l " " n n 15--(4--chlor~enyllbenzyl 3 "
9-flu~r~nyl 4 " "
4--chloropher~1 n n n n 4~ff~ny1 n n n n dipher~y~rethyl " anti--7--r~yl ..
a--(4-methylphenyl)benzyl " n n 1-diph~yllllet}~l 2 a- (4-chl~yl)b~1 3 phe~l 4 " " n 9--fluorenyl 3 4--me~1 4 " n diphenylIrethyl " "d~icyclo[3.2.1]oct~
p~yl " " " p~wlyl a--(4~hlo~yl) benzyl n n n H
3 0 diE~nylhy~t~yl " n n dipl~y~rethyl 3 "
9--flucxrenyl n n n 4--chlor~yl 4 " n b~yl " " " "
3 5 diph~ny~lrethyl 1~ "l-a~nnanty~thyl "
~3 Posi-~ o~
- (4~ylp~yl)benzyl 4 met~l l-adanantylnethyl H
c~--(4--chl~Yi) ~-- n n n n h~l diF~l 3 n n ~
9--~qUQ~l n n n n 4~t~ypl~yl 4 n n n W~l n n d:iph~ eth~ 1~1 H l~
--(4--ll~th~l)bel~l n n n n dipbe~l 3 n n n 9--fluor~l n n n n pb~yl 4 ll ~ n 4~yl ll n ll diE~y~et~Lyl " -C2H5 n he~ yl n n n ~yl a- (4~1) b~zyl " " " . H
a--(4--chl~yl)--a~ n n n n ~1 di~yl~thyl 2 " n n ~--(4--chlor~?henyl)b~1 3 n n n 9-fluorenyl ~ - n 4~t~ypenyl 4 " " "
n ll ll n diph~ylmethyl " " --(CH ) 7CH n c~--(4--chlo~henyl)b~zyl " n 3 d:i.Fberly~:e~Tl ~ n n ~-dipherlyl~ thyl 3 9--flut~ren~l ~yl 4 n n 3 0 b~zyl d:ipheI~yl~thyl " ' - (CH2) 4CH
a-(4-srethylph~yl)benzyl " " 1 3 cc--( 4--chlo~ophenyl ) b~l 3 3 5 9-fluDrenyl " " " "
. _ . . . _ .
M~ 335 ~ 14V~.~8 Posi--tio l o~
Substitu~nt Substi-(Rl Rl' or Rln) uent . R~ R3 A
10,11 dilyd~ 3 n~ut~rl (C~2)14CEI3 H
5~di~z= [a,d] ~c~eptcr~yi 4~e1~ ~1 4 ~ n n 4~cro~zyl n n n n d~henylmethyl ~2CE~=CH2 n a--(4~hlcrc~yl)b~zyl n n n n di.p}~y~d~l~l n n n n --(4--chl~1)b~1 3 n n n 9--flu~yl n n n n 4~c~ henyl 4 n n n b~l n n n n d:i.ph2n~1mPthyl ~ C~2) 4 2~5 5--h~d~5E~di~o n [a,d] cy~:lc~5-yl a--(4--srethylp~yl)b~nzyl n n n ~
a--(4~y1)~ n n n ~yd~l dipheny~ yl 3 n n n 9--fluorenyl " n 1~ I~
E~enyl 4 " " "
4--chlo~1 .. .. n . n diph~Iyl~ ncis--(CH2)5C~H(CH2)10CH3 a--(4~71phenyl)b~rl n l~ n l~
dip}~31ydr~1 " " " "
a- (4-chlo~p~enyl)b~zSr1 3 " n 1~
9--flu~renyl " n ~ n 2 5 phenyl 4 ~ .. ..
4--~y~l " n n n diPh~Y~rethyl " l-CH2C~
a--(4--Irethylp}~yl)benzyl n n n diPhe~llyd~ycet~yl " " " "
3 0 10 ~ dilyd~5H-dib~zo n n n [a,d] :yclo~5-yl dip~31rethyl 3 " n 9--fluarenyl " " n 1~
4-n~h~yp~:yl 4 " " "
~ll401 ,~l8 Posi-~ o~
&b~tituerltSl~bsti-(Rl RL~ 0~ Rln) t~t R2 R3 A
benz5~1 ~ 4 n~ CH2C-~ H
d~et~l n ~ CH2) 6C~
a- (4~10r~1)benzyl S phe~l n n 1~ phe~l ~ (4~tb~1)-a-- n n n H
~yl a--(4--chlor~1)benzy1 3 n n n 9--flu~rl n n n l~
~yl 4 n n n 4~ n ~
d~l n ~ ?l n a- (4-met}~tlphe~l)b~ylzyl n ~l 4-chlor~1 ..
a- (4~1O~-yl) ~- " n4-sr~Yl~Zyl "
~dss:~yl di l~yl~ 1 2 . n d~ ret~l 3 " 4~h~ny1 9--flua~enyl n n 1~ n yl 4 b~tl n 4~reth~1 " "4~thylbenzy1 "
diph~l " " phenethyl --(4--Iletb~l)benzyl " " n ~1 3 ~ n 9--~dr~9--fluorenyl 4 ~ yl ~- n n n 2 5 4-chlor~benzyl dip~lyllllethyl n n ex~2~ yl ~~(4~ylE~he~1)be~1zyl diFa~y~EI hyl n ~I n n a- (4-chlor~r1)b~zyl 3 " "
3 o 9--fluore~l n n 4~ cyE~yl 4 b~lzyl ~ n diF~exlyl~l~thyl n 1~eI~2--rx)~o~lyl ~- (4-chl~1)benzyl " " " "
~ M~ 335 ~L4~
tion of tR~., R~', o~ Rln) uent_ R2 R3 A
a- (4-met~ 4n-}~u~l erx~2-nor~ l H
dip~ln~yl 3 " "
9--fluor~yl n n n n 5 Ehe~l 4 n 1~ n ~h5~1 n ~ n n dip~nethyl n n l~th~l n a--u~l)b~Tl " n n 1~
~x--(4~ph~lyl ) ~-- n n n n 10 phenyl .. n 1~ phenyl o~--(4~1~æhenyl) ben~l 3 n n H
9--fluorenyl n n n n p~l 4 n n n benzyl n n n n 15 dipeny~Ilet~l " " l-a~an~tyl n a--(4~eth~phes~1)benzyl " n n n di~iheny1lyd~et~ n diE~y~et hyl 3 n 9--f lul~renyl n n l~
20 4-chlor~yl 4 " " "
4--chl~yl " ~I - n dip~yl~et}~l ~I n2--biCyclo[2.2~2]octyl --(4~hylp~enyl)ben~1 " n ll n a- t4-chl~rcphen~l)-a- " " "
~1 25 a- (4-chl~r~yl)b~zyl 3 n ll ll 9-flu~enyl " " " "
phE~lyl 4 n n n 4~e~1 1~ n dip~ly~I~etbyl ~ ~ ~-7-~ yl 30 a-(4~l~1p~1yl)benzyl n ll dip~eny~ rethyl " " n diEibenyl~rethyl 3 " " "
9-flu~enyl ethyl 2 n r~
1~4V~
Posi--tiOIl of Substil:uentSubsti-(Rl, Rl', c~r Rl") uent R2 R3 A
4tret~=y~y1 4 ~utyl an~i-7~y1 EI
4~hl~yl n n n diFb~;ylllethyl " endo~i~yclo[3.2.11a~
--(4-ilet~E~l)~eslzyl n n n n a--~4--Irethylphe~71~---- n n n n IydmY~l , a--(4--chlarc~l)~lzyl 3 n n n 9--flu~c)~l n E~yl 4 " n n 4--*eth~1 n " n n dipb~yllr~thyl " "l--ad~ntyllrethyl ~~ (4--~letb~l)b~lzyl n l~
dipheny3~yd ~ y ~ ~hyl " " " n diphenylmethyl 3 " n "
15 9~fluorenyl n ll phenyl 4 ~ n bg~z~l n n n n ~-(1,4-biphenyl)benzyl " H H "
~-~1,4-biphenyl)benzyl n C~ ~(CH2)7CH3 "
20 -(1,4-biphenyl)benzyl "n-butyl phenethyl n 2,2-dipbeny1ethy1 " H H "
2,2-diphenylethyl n CH3 -(CH2)7CH3 2,2-dipheny1ethyl "_-butyl phenethyl "
4,4-diphenyl-n-butyl " H H "
4,4-dip~enyl-nrbutyl n CH3 -(CH2)~CH3 "
4,4-diphenyl-n-butyl "nrbutylphenethyl "
diphenylmethyl " Hdiphenylmethyl phenyl 3 CH3 " "
9-fluorenyl 4n-butyl " n 30 4-chic~obenzy1 " H3,3-diphenyl-n-prcpyl "
diphenylmethyl 3 CH3 " "
diphenyIhyd mxymethyl 4 n-butyl Posi-tion of Sub6tit~ent Substi-~ ', or ~ ~) uent ~ ~ A
phenyl(octyl)methyl 4 H H H
10,11-dihydro-5H-dltenzo 2 " -( ~ ) ~ n [a,d]eyclcheF~er-S-yl 3 5~-diben~o[a,d] n ~ n eye1 ~ 5-yl 5 pbenylnhByl)methyl 4 n (~) 6 n E~l (hexyl)~l n mB~yl~ (C82) 4CE~ OE H2CH3 n 10,11-dbhy~e-5H ~ o 2 " -(C ~) C~rH "
[a,d]eye1 ~ -5-yl 6 5E-dlte~zo[a,d] " " " n eyelQheptEn-5-y1 lO,ll~yd~5E~di~zD n ~h~l ~2C3 n [a~d]cyclohept2nr5-yl 10 5H-dikenzo[a,d] " " n cyclQhept~n-5-yl phe~yl(octyl)~ethyl 4 " F~ yl n ~ 5 ~40~l.8 4s Example XVIII
Following t~Q procedure of either Example I or Example III, but substituting for the ethyl formimidate hydrochloride and 4-diphenylmethylpiperidine or N-formyl-5 4-diphenylmethylpiperidine and ethylamine, respectively, used therein, e~uivalent amounts of the appropriate starting materials suc~ as described in Examples XIII
and XVI, there are prepared the following:
(C~2)n ~
~ ~ NC-NR
Position of 10 Su~stituent n ~ R
_ 2 3 3 0 H n-octyl 3 0 H _-dodecyl 4 0 H n-hexadecyl 4 CH3 n-octyl 4 0 n-butyl n-octyl 3 1 H n-octyl 3 1 H n-dodecyl 4 1 H n-hexadecyl 4 1 CH3 n-octyl 4 1 n-butyl n-octyl 3 2 . H H
3 Z H n-octyl 3 2 H n-dodecyl 4 2 H n-hexadecyl 4 2 CH3 n-octyl 4 2 n-butyl n-octyl ~4~
EXAMPLE XIX
Following the procPdure of either Example I or Example III, but suhstituting for the ethyl formimidate hydrochloride and 4-diphenylmethylpiperidine or N-formyl-4-diphenylmethylpiperidine and ethylamine, respectively, used therein, equival~nt amounts of the appropriate starting materials such as descri~ed in Examples XIV
and XVI, there are prepared the following:
\ /
. A~
~ NC--NR3 ~O>
~ H
H n-octyl H n-dodecyl H n-hexadecyl c~3 n-octyl n-butyl n-octyl H H
H n-octyl H n-dodecyl H n-hexadecyl CH3 n-octyl n-butyl n-octyl H H
H n-octyl ~ n-dodecyl H n-hexadecyl CH3 n-octyl n-butyl n-octyl MN.335 1~4V1 18 EXAMPLE XX
Following ~he procedure of either Example I or Example III, but substituting for the ethyl formimidate hydrochloride and ~-diphenylmethylpiperidine or N-formyl-4-diphenylmethylpiperidine and ethylamine, respectively, used therein, e~uivalent amounts of the appropriate starting materials suc~ as described in Examples XV and XVI, there are prepared the following:
(C6H5) 2C~\
\ NC=NR3 Position of 10 Substituent n R2 R3 2 0 H _-octyl 3 0 H _-dodecyl 3 0 H n-hexadecyl 4 0 CH3 n-octyl 4 0 n-butyl n-octyl 2 1 H _-octyl 3 1 H n-dodecyl 3 1 H n-hexadecyl 4 1 CH3 n-octyl 4 1 n-butyl n-octyl 2 2 H n-octyl 3 2 H n-dodecyl 3 2 . H n-hexadecyl 4 2 c~3 n-octyl 4 2 n-butyl n-octyl 114() EXAMPLE XXI
N-[4-(Diphenylmethyl3-1-piperidinyl]
methYlene benzenebutanamine (E)-2-Butenedioate Hvdrate , A ~ixture of 4.40g (0.016 mole) of N-formyl-4-(diphenylmethyl)piperidine and 1.47 ml (2.00g, 0.015 mole) of dimethyl sulfate was heated in a steam bath for three hours at 100C under anhydrous conditions until homo-geneous. The mixture was cooled, dissolved in 30 ml of methylene chloride and treated with 2.50 ml (2.36 g, O.016 mole) of phenylbutylamine. The resulting solution was stirred for three hours and treated with 6 ml 3 N
sodium hydroxide solution with vigorous stirring at 0.
The organic layer wa~ separated, dried over potassium carbonate, filtered and evaporated ~o an oil. This material was dissolved in isopropanol, treated with 1.84g of fumaric acid and cooled. There was filtered off a white crystalline solid which was recrystallized from ethanol to give N-14-(diphenylmethyl)-1-piperidinyl]-methylene benzenebutanamine (E)-2-butenedioate hydrate as a white crystalline solid, m.p. 207-208.5C.
EXAMPLE XXII
~-(Diphenylmethyl)-l- l-[me~hyl(octylimino) methyl]-piperidine Monoperchlorate .
A mixture of the fluoroborate salt of N-octyl-acetimidic acid ethyl ester ~generated from 5.68g [Q~04 molel of boron trifluoride etherate, 2.77g [0.03 mole]
of epichlorohydrin, and 5,80g t~.~34 mole] of N-octyl acetamide) and 5~ ml of ether was treated with 4 ml ~2.92g, 0.029 mole~ of triethyl amine~ Filtratio~ and evaporation of the filtrate afforded a liquid residue whic~ ~as dissolved in 120 ml dry toluene~ To this solution was added 6.00g ~0.024 mole) of glacial acetic acid and the resulting solution was stirred at 50C
over 4A molecular sieves under a nitrogen atmosphere for four days. The reaction mixture was cooled and neutralized by ~haking with 3 N sodium hydroxide solu-tion. The organic layer was separated, dried over X2C03, filtered and stripped to an oil which was distilled.
M~ 33s l~LV~
4g The pot residue was dissolved in ether and perchloric acid and methanol added. Cooling the solution pro-duced a solid fraction. Filtration afforded a crystal-line solid whi.ch was recrystallized three times from S methanol to give 4-(Diphenylmethyl)-l- l-[methyl(octylimino)-methy]~piperidine Monoperchlorate as a white crystalline solid, m.p. 119-121.5C.
EXAMPLE XXIII
a-(4-Methylphenyl ? -a-Phenvl-4-~yridine Methanol A solution of 0.05 le of 4-methylphenyl magnesium bromide in 500 ml of anhydrous ether was treated with 4-benzoylpyridine in S00 ml anhydrous ether.
After stirring the n~lting m~re for 1.5 hc~rs at 25, an ~æ~s soluticn of a~L~ium ~ik~ide was ~ causing a solid to form which waQ filtered. Recrystallization of thi~ material ~rom 95% ethanol afforded the desired ~-(4-methylphenyl)-a-phenyl-4-pyridine methanol, ~.p. 192-135C. The corresponding 4-chlorophenyl (~.p. 198-202C) and 4-methoxyphenyl (~pO 204-206C) derivatives were also prepared by the same method, using equivalent amounts of the appropriate starting materials.
EXAMPLE XXIV
x-(4-Methylphenyl)-a-Phenyl-4-Piperidine A solution of 25~0g (0.09 mole) a-(4-methyl-phenyl~-a-phenyl-4-pyridine methanol, 55 ml of 47-Sl~
hydriodic acid and 180 ml of acetic acid was refluxed overnight, cooled, and poured into aqueous sodium bisulfite. This solution was made basic with sodium hydroxide and extracted with methylene chloride. From the organic layer there was isolated an oil which was reduced at 40 psi over platinum oxide at 60-65C in acetic acid following the method of United States Patent No. 3,267,108. The excess acid was removed and the residue made ba~ic to give a-(4-methylphenyl)-a-phenyl-4-piperidine which was characterized as its fumarate salt, m.p. 157.5-161.5C (Hoover). The corresponding 4-chlorophenyl (m.p. 175-178C; fumarate salt) and ~, ~14 sn 4-methoxyphenyl (m.p. 94-98C; free base3 derivatives were also prepared by the same method, using equivalent amounts of the appropriate star~ing materials.
. EXAMPLE XXV
s -(1,4'-Biphenyl)~l--phenyl-4-pyridinemethanol A solution of 111.0g (0.50 ~ole) of 4-biphenyl bromide in 200 ml of dry ~etrahydrofuran ~THF) was added slowly to a mixture of 12.10g (0.5 gram-atom) of mag-nesium, 2 ml o~ ethylenedibromide and 200 ml of T~F at such a rate as to maintain reflux. After addition the mixture was refluxed for 0.5 hours, cooled and treated over 0.5 hours with a solution of 82.3g (0.45 mole) of 4-benzoylpyridine in 600 ml THF. The resulting slurry was stirred 0.5 hours at 25C and treated with 1000 ml 20% ammonium chloride solution. The organic layer was separated, filtered, the filtrate dried, filtered and stripped. The residue was triturated with ether and filtered. This solid was recrystallized ~rom ethanol, chloroform, and finally toluene to give a-(1,4'-biphenyl)-yl-a-phenyl-4-pyridin methanol as a white solid, m.p.
after drying in vacuo at 70C; 173.5-175.5C.
EXAMPLE XXVI
_ a-(1~4'-Biphenyl)yl-a-phenyl-4-~iperidinemethanol A solution of 10.00g (0.030 mole) of a-(1,4'-biphenyl)yl-a-phenyl-4-pyridine and 160 ml of acetic acid was hydrogenated in the presence of platinum oxide (1.Og) at 25-35 psi at 70-90 on a Paar shaker. After hydrogen uptake ceased, the mixture was filtered through dicalite and evaporated to a solid residue. This residue was slurried in water, made basic with 3 N NaOH and ex-tracted with chloroform. The chloroform layer was dried over potassium carbonate, filtered through dicalite and evaporated. The residue was dissolved in toluene and cooled. The resulting solid was filtered and recrystal-lized from toluene to give a-~1,4'-biphenyl)yl-a-phenyl-4-piperidinemethanol as a white solid; m.p. 185-186.5C.
481.1)3 EXAMPLE XXVII
9-(4'-~ eridinYll-9-fluorenol A sslution of 13.0g (0.05 mole) of 9-(4'-pyridyl)-9-flu~renol in 200 ml of glacial acetic acid was hydrogenated over 0.8g of platinum oxide at 40 psi.
The mixture was filtered, stripped, and the residue made bas~c affording 9-(4'-piperidinyl)-9-fluorenol.
EXAMPLE XXVIII
4-Fluorenylidenepiperidine A suspen~ion of 13.0g (0.05 mole) of 9-(4'-piperidinyl)-9-fluorenol in 70 ml of 48% sulfuric acid was heated on a steam bath for ~even hours and poured on to ice. The resulting solid was filtered, made basic with sodium hydroxide solution and extracted with methylene chloride. The organic layer was qeparated, dried over potassium carbonate, filtered and stripped to give 4-fluorenylidenepiperidine.
EXAMPLE XXIX
9-(4'-Pyridyl)fluorene A solution of 1.35g (0.005 mole1 of ~,a diphenyl-4-pyridine methanol in 18.5 ml of 97% formic acid was treated dropwise with 8 ml of concentrated sulfuric acid.
The r~action was refluxed ten minutes, cooled and made basic with 6 N sodium hydroxide solution causing a solid to separate. This material was filtered and recrystallized from me~hanol to give 9-(4'-pyridyl)fluorene, m.p. 141-143C (Hoover).
EXAMPLE_XXX
9-(4'-PiPeridYl)fluorene fumarate A solution of 54.75g (0.225 mole) of 9-(4'-pyridyl)fluorene in 600 ml of acetic acid was hydro-genated over S.Og of platinum oxide at 40 psi and 25C.
The mixture was filtered, stripped and made basic, afford-ing 9-(4'-piperidyl)fluorene, which was crystallized as the fumarate salt, m.p. 228-230C (dec).
isonitrile, 0.26g (0.002 mole) of silver chloride, and 10 ml of toluene was stirred 48 hours at 25, filtered, stripped, and the residue dissolved i~ methylene chloride.
Extraction with 10% sodium hydroxide, drying and filtra-tion of the organic layer followed by evaporation afforded 4-(diphenylmethyl) l-[(octylimino)methyl]piperidine isolated as the fumarate salt, which was identified by thin layer chromatography.
EXAMPLE XI
Following the test procedure previously des-cribed, the following compounds were tested for their antisecretory activity. The ED50 values for p.o.
administration and the percent inhibition for i.d.
administration at 20 mg/kg are tabulated below (Ri =
H except where noted):
~1 R~ R2 A~NC=NR3 . _ . . ... , _ _ _ .. _ . . , .. _ . . ~
MN
~4~ ~8 O O O O ~O O ~D ~ ~ ~ ~ a~ c o ~o o o ~ In ~
~ O O O O O 0~ G 0 t~ ~ t~ O O ~ t` ~0 o 8 '` ~ ~ co ~ .` 'D ~ ~D ~ o ~ ~ ~
u~ C ~r o o ~ CD CO ~ ~ u~ ~ CO ~ ~` ~O ~ ~ O O O
k~ ~ ~ A V
~N ~J
1 ~ t ~ I r : ~ e .
~3' r~
l.8 ~3 a ~
o ~ O N t` C~ W 0~ ~
o o In ~ co I o ~ +~+U- ~
~I cl ~14V~ ~8 2~
EXA~?LE XII
Following the procadure described by Buehler and Pearson [Survey of Organic Syntheses, Ch. 18, p 894 (1970)] and using the appropriate substituted piperidine and anhydride, there are prepared the following piperidine S amides, wherein the following substituents are in the two (Rln), three ~Rl') or four ~Rl) position:
1~ Rl" , 1 ~ .NC=O
A ~ R2 Position of Substituent S~i~t ~ A
dipbeny~ yl 4 H H
c~ (4~11t~he~1)bq~1 n n n (4~rethylEiher~1) b~l n ~ n (4~1~9/~l)be~l n n n ct~ (4--chl~phe~l)}~l 3 9--fluor~l ~ n n d~hes~l n ~ n ph~yl 4 n phe~l n 4 ~ lar ~ yl " " H
4-chl~rcpheny~ " " phenyl 20 4-methcxypheny1 " " H
4-methcxyph~nyl " " phenyl 4-chlordbenzyl n n H
phenyl " methylphenyl pbenyl n n-butyL phenyl 25 o!(l,4-bipbenyl)benzyl " H H
or(l~4-biphenyl)b#nzyl " methyl o-(1,4-bipbenyl)henzyl " n-butyl n 2,2-dipheny1ethy1 " H "
2,2-diphenylethyl n methyl 30 2,2-diphenylethy1 ~ n-butyl "
10,11-cbhydrc-SH-dikenzo[a,d]-cycloheptene-S-yl 2 H "
~4V~
25 ~ositic~n of Su~tih~t Substituent ~ A
10,11~ ~5H~Z Ea~d] -qk~hept~5-yl 2 ræt~yl H
n n rs--~l~l n n- 4 H "
n " meff~yl n n--but 4,4~1-n-}~1 4 H ~
4 ~ 4~1~ l n T~l n 4 ~ 4~ l nn--butyl n 4~th~1 n H ~
benzyl - - n 9--f Lu~l n n n dip~3met~1ene n n -~-(4~1)~1 " " "
--(4~1p~yl)bOE~ n ~~ (4~1) be~ tl n n n dipe~l 3~ " "
Y~Y1 2 0 a--(4~hl~1) b~l n n n pheryl 4 n n 9--fluore~l n n n 4--chlxo~ - n 4~1 n n ~
2 5 4~c~1zyl n 1~ n 4~e~1 1~
~zyl .. .. ..
dipher~ylmethylene n n n a-(4~orc~yl)b~zyl " " "
(4~ctl~1) b~zyl ~' n ~
- (4~ret~1F~yl) b~zyl " " "
diE~henylme~yl 3 " "
9-flu~renyl 1. " "
~lw~l 4 " "
--(4--chlor~yl~b~zy1 3 n Positic~ of Substitu~t S~ entR~ A
5~o[a,d]cyc~5-yl 2 H H
n n me~l n n n--bu~yl lO,ll~ydro ~a,d] ~yc~5-yl n E~ n " " me~l "
n n n~ 5~1 n E~Tl (oc~l)mEt~l 4 H n n ~ yl n " n-h~l phe~l ~h~l)m~l ~ H
n }~1 n n n ~b~l n p~e~l n n n W~l n ~ n 4-ræ~1 n 1~ n be~l n n n Wllc~l ~I n n 4~ _1 n n n q~l 2 H n diE~yl n ~1 di~ lmethyl n n-butyl 5H~szota,d]cycloh~J~s-~-yl 4 H n 5~-d~#~c[a,d]cyclohq~5-yl n methYl n 5~d~x~o[a,d~cycJ~ en-5-yl " n-butyl EXAMPLE XIII
Following the procedure described by Buehler and Pearson [Survey of Organic Syntheses, Ch. 18, p 894 (1970)] and using the appropriate substituted piperidine and anhydride, there are prepared the following piperidine amides:
,~, s~
2)n Po~ition of Substituent n R2 n n CH3 S n n n--butyl " 1 H
n ~ CH3 n n n-butyl " 2 H
n n CH3 n 1l n-butyl-n n CH3 " " n-butyl " 1 H
n n CH3 n ~ n-butyl " 2 H
" " CH3 2 0 n n n-butyl 1~4~
EXAMPLE XIV
Following the procedure of Example XIII, there are prepared the following piperidine amides:
~,, ~ NC=O
wherein R2 = hydrogen, methyl~ or n-butyl.
EXAMPLE XV
Foll~wing the procedure of Example XIII, there are prepared the following piperidine amides:
(C6HS)2C ~\
~`NC80 10Position of Substituent R2 " CH3 " n-butyl n CH3 n n-butyl " CH3 n n-butyl 1~4~.8 EXAMPLE XVI
Following procedures describPd in the references given above for compounds o~ Formula ~III), the following are prepared: 1l IH
~2 R3 H -(CH2)llCH3 (CH2)7CH3 H -(CH2)l4CH3 H -(CH2~4CH-CHCH CH
Hcls-(cH2)5cH=cH(cH2)locH3 ( 2)6C_CH
H 4-ClPh-H 4-MeOPh-H 4-MePh-H -C~2C--CH
~ exo-2-norbornyl H endo-2-norbornyl Hl-decahydronaphthyl H l-adamantyl H2-bicyclo[2.2.2]octyl Hanti-7-norbornenyl Hendo-bicyclo[3.2.lloctyl Hl-adamantylmethyl Me H
Me -C2H5 Me -(CH2)5CH3 Me -(CH2)7CH3 Me -(CH2)l4CH3 Me-(CH2)4CH=CHCH2cH3 Meclg-(CH2)5CH=CH(CH2)loCH3 Me -CH~C-CH
Me (CH2)6C--CH
Me Ph Me 4-ClPh-Me 4-MeOPh-Me 4-MePh-Me PhCH2-Me 4-ClPhCH2-Me 4-MePhCH2-M~ 335 ~4(~
Me 4-MeOPhC~2-Me 2CH2 Me exo-2-norbornyl M~ endo-2-norbornyl Me l-decahydronaphthyl ~e l-adamantyl Me 2-bicyclo[2.2.2]octyl Me anti-7-norbornenyl Me endo-bicyclol3.2.1]octyl Me 1-adamantylmethyl n-Butyl H
l-nBU" ) Bu C2H5 Bu -CH2CH=CH2 Bu (CH2)7CH3 Bu (CH2)14CH3 Bu -(CH2)4CH=C~C2~5 Bu cis-(cH2)5C~=CH(cH2)locH3 Bu CH2C-CH
Bu ( 2)6C-H
Bu 4-ClPh Bu 4-MeOPh Bu 4-MePh Bu Ph Bu PhCH2 Bu 4-ClPhCH2-Bu 4-MePhCH2-~u 4-MeOPhCH2-Bu PhCH2CH2 ~u exo-2-norbornyl Bu endo-2-norbornyl Bu l-decahydronaphthyl Bu l-adamantyl Bu . 2-bicyclo[2.2.2]octyl Bu anti-7-norbornenyl Bu endo-bicyclo[3.2.1]octyl Bu l-adamantylmethyl H diphenylmethyl Me diphenylmethyl Bu diphenylmethyl H 3,3-diphenyl-n-propyl Me 3,3-diphenyl-n-propyl Bu 3,3-diphenyl-n-propyl ~40~ 18 EXAMPLE XVII
Following the procedure of either Example I or Example III, bu~ substituting for the ethyl formimidate hydrochloride and diphenyl-4-piperidylmethane or N-formyl-4-diphenylmetXylpiperidine and ethylamine, respectively, used therein, equivalent amounts of the appropriate starting materials such as described in Examples XII and XVI, there are prepared the following, wherein the following su~sti~uents are in the two (Rln), three (Rl'), or four (Rl) positions:
Rl l Rl n Rl ~<
A--\_~NC=NR3 Posi--tion of S~x*itNent S~x~i-~ ', or ~n) uent ~ R3 A
d~nylmethyl 2 H H H
dipheny~ yl 3 n ~ n 15 9-fluorenyl " n n n c~--(4~1)berlz~1 n n n "
di~ f~Nymethyl 4 " " n 10,11-dihy~x~5~ ~zo "
[a,d]cycloh~en-5-yl 4--chlon~x~y1 n n 20 4~o~enyl dipheny~E~l n n (~)11CH3 4~hlD~l n a-(4-methylphenyl)benzyl " " " "
4-chlorokenzyl n n n ~--(4~hl~1)--tY-- l~ n ~ydm~1 a-(4-~ophenyl)ben2yl 3 " " "
9-fluorenyl ~ n 4-metbI~uy1 4 " -(CH2)7CH3 9-~luorenyl 3 " n dipbenyl~y~s~ymethyl 2 a-(4~o~pY~y1)benzyl 3 " n 1~4V~
Posi--~ o n ) uent R2 R3 A
diph~nylhy~raxy~yl 4 H - (CH2) 7CH3 H
51~dikG~o[a,d3 n ~yc~hep~-5-yl yl n d~l (CH2) 14CH3 ~1 cr ~4--chlon~pherlyl ) b~lzyl 3 " " n 9-flu~renyl 4 " " "
~ 14-methyl~henyl)benzy1 "
4~hloq:c~1 n n n n ~1 " l~ ,. "
di~henylmet~yl " -(CH2)4C~I2CH3 ~E~l)benzyl n d~l8~t~1 3 10~11~5~ y_ ~
5}~dil~lzo [a,d] cyt:ld~5-yl 9--fll~lyl n ~ n di~ly~ret~lyl 4 ph~yl " " " "
~ ~l n ~ n diphenyl~ thyl n ~ CLs--(CEI2) cE~(CH2)10CH3 c~~ (4~hla~?he~1)b~zyl 3 9-~9-flUDl~T1 4 --(4~hl~lyl) ~~ I- ~ n n ~1 4~et~:yl " " " "
2 5 berlzyl ll ll ll n cr (4~1~ yl)be~1 n dip~Iylmethyl n " (CH2) 6C{~
a- (4-chlor~pbenyl) benzyl " " " "
~1 3 0 9-fluar~nyl 3 " " "
a-(4-chlorop~enyl)benzyl " " " "
dip~ylTrethyl 2 .. " n Posi--~ o S~nt S~
, R~ ', or Rln) uent ~2 .R3 A
}~1 4 H (C~z) 6C-CH . H
4--~leth~l n " n n d~T~ E~l n n --CH2C ~{ H n a--(4--leti~l)b~l n n a--(4~tly1p~1) ~-- n ~ n n ~1 --(4~L)berlzyl 3 " n n 9--fll~l 4 n n n [a,d] ~c1~5-y1 10 4~ethNyE~h~l n n n E~yl 4~hlo~c~1 n ~ n H
dipb~ n n exc~--2~1y1 n a- (4~et~y1p~1) b~1 " " ~ n a--(4~1)--a-- n n n n ~1 diF~lmet~l 3 n n n 9--flu~l ,. n E~yl 4 " n n 4-chLor~ibenzyl n n ~ n ~-(4~hlar~yl)b~zy1 " " en~2-nor~ornyl "
diphe~ethyl " n n di~enyl~ ~ethyl a-(4-chlorop}~yl)benzyl 3 9--flu~l ~ .. n n 4~y~yl 4 " " "
b~zyl ~ .. "
di~enylIrethyl ~ nl--deca~ydr~phthyl n a- (4~yl) b~zyl " n ~- (4-methylp~yl)--a- n ~b~l dipheny~thyl 3 "
9--fluorenyl ~ .- n ~
p~enyl 4 " " "
4-chlor~l ~- (4-meth~yl)benzyl " " l~nantyl "
~14 Posi-tian o~
Sl~bstituent Su~
(Rl, Rl', ar Rln) uent R2 R3 A
10 ,11--di3y~5-~dr~ 4 H1-ad~nan~yl H
5}}di~ ta,drc~yc~5-yl ~~ (4~hlo~l)_a_ n n ~ n ~1 a--(4~1)b0zy1 3 n n 9--flg~l n ~-4--chl~l 4 n n F~l n n n El diph~et~l n n2-bic~yclo~2.2.2]oc~1 -(4-~retl~1)~enzy1 " " " "
d~ ~Crc~l " n n n diphen~l 3 n n n 9--fluore~l 4 n n E~l .. n n 4~etho~1 ~ n n n 15 dip} ~ ~rethS~l n a ~ -7-I
-~4-c~lk=~ enyl)benzyl " n n ~-(4 m~Lhylphenyl)-~- n n ~1 dipheny~mEthyl 3 n n -9-fluorenyl " " " "
20 phenyl 4 n n 4-~hlorobenzy1 " " " "
diphenylmethyl " " enlo-bicy~10[3.2.1]octyl o-(4-methylpheny1)benzy1 " " n n diphenyIhydroxy=ethyl n n n ~
25 ~-(4-chlorcpbeny1)benzyl 3 " " "
9-fluorenyl n n dipbenyIhydr=xymethyl 2 " " "
4-methcxypbenyl 4 " " "
b ~ zyl " n n 30 diphenylmethyl " "l-adamantylmethyl "
-(4-methcxyph~=yl)benzyl " " n n a-(4-chlo ~ 1)_o_ n n hydrax ~ l a-(4-chlorc~henyl)benzyl 3 V~ ~ ~
Posi--tion o 9-flu~l , 3 Hl-adamantyl~1 H
phe~l 4 n ~ . n 4--sw~l n ~ n n diE~3~1m~1 laeth~l H n --(4~1)~1 n n ~ n a--(4--chl~Yl)~~ n n n n ~1 5--~51~di~1zo n n n n [a,d] c:ycl~-5-yl ~ (4~yl)ber~ 1 3 ~ n 9--fluorer~1 n n n diEhel~lmeff~l 2 n n ~
4--chlcl~l 4 n n 1 be~l n n 11 n t~ (4--llethc~phe~l)be~l ~I n n n a--(4~ylpt~nyl)--a-- n n ~ n ~1 dip~yl~ }~l 3 n 1~ n 9--h~r~9--flua~l 4 n n ~
4~th~y~yl " " " "
2 0 10 ,11 di~yd~5i}di~eDzo [a,d] cycl~-5-yl b~lzyl ~- n (~(4~1phe~lyl)be~lzyl n --(CH2)7CH
dipher~llyd~ynet~yl n a- (4~hlo~1)~1 3 n 2 5 9--fluor~l p}~l 4 " " "
be2~zyl ~ n n dipheny~nethyl " "(~ H2) 14CH3 a- (4~hl~phen~1)benzy1 " " "
3 0 a- (4~ret~y1) ~ " "
hydm~yl dipherlyln~l 3 " " "
9-fluoren~l " " "
Posi ti~l of o~ Rln)uent R2 R3 4~etlcyphenyl, 4 I~etl~l(CH2) 14CH~ H
4--chlorobenzyl " n n n d:i~y~hyl " n--CH2CE~=CH2 n a--(4--~l~ti~l)b~ln n n n l n r n Eh ~1 n n ~ H
a-~4~1)bq!1 3 " " n 9--flu~re~yl n n Il n 4--chlor~henyl 4 bq~l " " " "
dipe~lllet~l n n~ (CH2 ) 4CE~H2CH3 a--(4~ethylphe~1)be~1 n n n n a--(.4~bl~Y1)~-- n u n n ~1 di.E~ylIIethyl 3 n n n 9~fluorenyl l 4 n n n 4-chlorobenzyl " ~ n n diphenylmeth yl ~- n Cis--(CH2~5C~=CH( ~ )10 3 a-(4-methDxyphenyl~ken2yl" " " n diphenYlhydroxymethyl " " " "
g-flu~renyl 3 n a-~4-chl~opheny1)benzyl " " n 4--me~/l 4 ~ n 25 b~lzyl ll 1' ~I ll a--(4-methylphenyl)benzyl n l~ n a-(4-chlorcphenyl)-a_ " "
}~1 phenYlmethyl 3 " n ll 30 g-hydroxy-9-fluorenyl 4 " " "
~yl "
4-metho~ybenzy1 dipbenylmethyl n n~ (CH2) 6C---CH n a-(4-chlorophenyl)benzyl " " n diphenyIhy~roYymet~yl " " " "
l8 Posi-tion of S~b~t S~
(R~., Rl', or Rl") uent ~ R3 A
dip~y~e~l 3 nE~yl--(CH2)6C~CH H
9--f luorer~l n n n n diFbe~lly~3~1e~1 2 " n n 4~hlc3~ 4 ~ n diphe~l~E*}~l n n benzyl n a-(4~p~1)benzy1 " " 4-chlc~e~1 "
diphe~Tlh~ 4~
diEihe~y~l 3 " 4~1b~1 "
10 ~ dih~5--~n n n n 5}}dib~zo [a,d3 c:yc1at~5-yl 9--fluor~Tl - n "
-(4~yp~1)~enzyl 4 " 4~ora}~nzyl "
4--chlor~benzyl " ' benzyl n diph~ny~ yl " " ~2~ ornyl n a--~4~eth~1pbenyl) b~zyl n 1- n n ~Iyl ~ n n p~ enyl diphe~ynet~l n ~ n H
diph~nylmRthyl 3 2 0 Eiber~l 4 n n 9--fluorenyl 3 ~. n ~1 4 ~ n 10,~ ydr~5E~dib~zo [a,d] c~clo~p~-~yl dip~ny~rethyl ~ " ~2-n~ornyl "
a-(4 chlorc~henyl)benzyl " " " "
--(4~net~1ph~nyl)~- n n n h~dra~l diF~y~rethyl 3 " " "
9--fluorenyl n n n n 4~reth~p~enyl 4 " " n 3 o 4~or~zy1 " " " "
dip~yl~thyl " " l--decalyd~p~thyl n - (4-~y~l)benzyl " " " "
dip~y~t~l " " "
-(4 chl~1)benzyl 3 " " "
~ 335 1~4~
Posi-ti~ of Substituent Sl~bSti-(Rl, Rl', or RLn) uent R2 R3 A
4~hlQ~yl 4 n n n 4--net~yb~1 n n n n 5di~lmet~l n n1 a~~
~- (4~hlom~y1~benzy1 n ~ n n --(4t~ n n ll n h~drax~l dip~ylIl~l 3 n n n 9--flu~r~yl " " n n E~l 4 " " "
benzyl diphe~et~l n n2--bi~yclo[2.2.2]oc~yl "
dip~Dydr~l " " n n 15--(4--chlor~enyllbenzyl 3 "
9-flu~r~nyl 4 " "
4--chloropher~1 n n n n 4~ff~ny1 n n n n dipher~y~rethyl " anti--7--r~yl ..
a--(4-methylphenyl)benzyl " n n 1-diph~yllllet}~l 2 a- (4-chl~yl)b~1 3 phe~l 4 " " n 9--fluorenyl 3 4--me~1 4 " n diphenylIrethyl " "d~icyclo[3.2.1]oct~
p~yl " " " p~wlyl a--(4~hlo~yl) benzyl n n n H
3 0 diE~nylhy~t~yl " n n dipl~y~rethyl 3 "
9--flucxrenyl n n n 4--chlor~yl 4 " n b~yl " " " "
3 5 diph~ny~lrethyl 1~ "l-a~nnanty~thyl "
~3 Posi-~ o~
- (4~ylp~yl)benzyl 4 met~l l-adanantylnethyl H
c~--(4--chl~Yi) ~-- n n n n h~l diF~l 3 n n ~
9--~qUQ~l n n n n 4~t~ypl~yl 4 n n n W~l n n d:iph~ eth~ 1~1 H l~
--(4--ll~th~l)bel~l n n n n dipbe~l 3 n n n 9--fluor~l n n n n pb~yl 4 ll ~ n 4~yl ll n ll diE~y~et~Lyl " -C2H5 n he~ yl n n n ~yl a- (4~1) b~zyl " " " . H
a--(4--chl~yl)--a~ n n n n ~1 di~yl~thyl 2 " n n ~--(4--chlor~?henyl)b~1 3 n n n 9-fluorenyl ~ - n 4~t~ypenyl 4 " " "
n ll ll n diph~ylmethyl " " --(CH ) 7CH n c~--(4--chlo~henyl)b~zyl " n 3 d:i.Fberly~:e~Tl ~ n n ~-dipherlyl~ thyl 3 9--flut~ren~l ~yl 4 n n 3 0 b~zyl d:ipheI~yl~thyl " ' - (CH2) 4CH
a-(4-srethylph~yl)benzyl " " 1 3 cc--( 4--chlo~ophenyl ) b~l 3 3 5 9-fluDrenyl " " " "
. _ . . . _ .
M~ 335 ~ 14V~.~8 Posi--tio l o~
Substitu~nt Substi-(Rl Rl' or Rln) uent . R~ R3 A
10,11 dilyd~ 3 n~ut~rl (C~2)14CEI3 H
5~di~z= [a,d] ~c~eptcr~yi 4~e1~ ~1 4 ~ n n 4~cro~zyl n n n n d~henylmethyl ~2CE~=CH2 n a--(4~hlcrc~yl)b~zyl n n n n di.p}~y~d~l~l n n n n --(4--chl~1)b~1 3 n n n 9--flu~yl n n n n 4~c~ henyl 4 n n n b~l n n n n d:i.ph2n~1mPthyl ~ C~2) 4 2~5 5--h~d~5E~di~o n [a,d] cy~:lc~5-yl a--(4--srethylp~yl)b~nzyl n n n ~
a--(4~y1)~ n n n ~yd~l dipheny~ yl 3 n n n 9--fluorenyl " n 1~ I~
E~enyl 4 " " "
4--chlo~1 .. .. n . n diph~Iyl~ ncis--(CH2)5C~H(CH2)10CH3 a--(4~71phenyl)b~rl n l~ n l~
dip}~31ydr~1 " " " "
a- (4-chlo~p~enyl)b~zSr1 3 " n 1~
9--flu~renyl " n ~ n 2 5 phenyl 4 ~ .. ..
4--~y~l " n n n diPh~Y~rethyl " l-CH2C~
a--(4--Irethylp}~yl)benzyl n n n diPhe~llyd~ycet~yl " " " "
3 0 10 ~ dilyd~5H-dib~zo n n n [a,d] :yclo~5-yl dip~31rethyl 3 " n 9--fluarenyl " " n 1~
4-n~h~yp~:yl 4 " " "
~ll401 ,~l8 Posi-~ o~
&b~tituerltSl~bsti-(Rl RL~ 0~ Rln) t~t R2 R3 A
benz5~1 ~ 4 n~ CH2C-~ H
d~et~l n ~ CH2) 6C~
a- (4~10r~1)benzyl S phe~l n n 1~ phe~l ~ (4~tb~1)-a-- n n n H
~yl a--(4--chlor~1)benzy1 3 n n n 9--flu~rl n n n l~
~yl 4 n n n 4~ n ~
d~l n ~ ?l n a- (4-met}~tlphe~l)b~ylzyl n ~l 4-chlor~1 ..
a- (4~1O~-yl) ~- " n4-sr~Yl~Zyl "
~dss:~yl di l~yl~ 1 2 . n d~ ret~l 3 " 4~h~ny1 9--flua~enyl n n 1~ n yl 4 b~tl n 4~reth~1 " "4~thylbenzy1 "
diph~l " " phenethyl --(4--Iletb~l)benzyl " " n ~1 3 ~ n 9--~dr~9--fluorenyl 4 ~ yl ~- n n n 2 5 4-chlor~benzyl dip~lyllllethyl n n ex~2~ yl ~~(4~ylE~he~1)be~1zyl diFa~y~EI hyl n ~I n n a- (4-chlor~r1)b~zyl 3 " "
3 o 9--fluore~l n n 4~ cyE~yl 4 b~lzyl ~ n diF~exlyl~l~thyl n 1~eI~2--rx)~o~lyl ~- (4-chl~1)benzyl " " " "
~ M~ 335 ~L4~
tion of tR~., R~', o~ Rln) uent_ R2 R3 A
a- (4-met~ 4n-}~u~l erx~2-nor~ l H
dip~ln~yl 3 " "
9--fluor~yl n n n n 5 Ehe~l 4 n 1~ n ~h5~1 n ~ n n dip~nethyl n n l~th~l n a--u~l)b~Tl " n n 1~
~x--(4~ph~lyl ) ~-- n n n n 10 phenyl .. n 1~ phenyl o~--(4~1~æhenyl) ben~l 3 n n H
9--fluorenyl n n n n p~l 4 n n n benzyl n n n n 15 dipeny~Ilet~l " " l-a~an~tyl n a--(4~eth~phes~1)benzyl " n n n di~iheny1lyd~et~ n diE~y~et hyl 3 n 9--f lul~renyl n n l~
20 4-chlor~yl 4 " " "
4--chl~yl " ~I - n dip~yl~et}~l ~I n2--biCyclo[2.2~2]octyl --(4~hylp~enyl)ben~1 " n ll n a- t4-chl~rcphen~l)-a- " " "
~1 25 a- (4-chl~r~yl)b~zyl 3 n ll ll 9-flu~enyl " " " "
phE~lyl 4 n n n 4~e~1 1~ n dip~ly~I~etbyl ~ ~ ~-7-~ yl 30 a-(4~l~1p~1yl)benzyl n ll dip~eny~ rethyl " " n diEibenyl~rethyl 3 " " "
9-flu~enyl ethyl 2 n r~
1~4V~
Posi--tiOIl of Substil:uentSubsti-(Rl, Rl', c~r Rl") uent R2 R3 A
4tret~=y~y1 4 ~utyl an~i-7~y1 EI
4~hl~yl n n n diFb~;ylllethyl " endo~i~yclo[3.2.11a~
--(4-ilet~E~l)~eslzyl n n n n a--~4--Irethylphe~71~---- n n n n IydmY~l , a--(4--chlarc~l)~lzyl 3 n n n 9--flu~c)~l n E~yl 4 " n n 4--*eth~1 n " n n dipb~yllr~thyl " "l--ad~ntyllrethyl ~~ (4--~letb~l)b~lzyl n l~
dipheny3~yd ~ y ~ ~hyl " " " n diphenylmethyl 3 " n "
15 9~fluorenyl n ll phenyl 4 ~ n bg~z~l n n n n ~-(1,4-biphenyl)benzyl " H H "
~-~1,4-biphenyl)benzyl n C~ ~(CH2)7CH3 "
20 -(1,4-biphenyl)benzyl "n-butyl phenethyl n 2,2-dipbeny1ethy1 " H H "
2,2-diphenylethyl n CH3 -(CH2)7CH3 2,2-dipheny1ethyl "_-butyl phenethyl "
4,4-diphenyl-n-butyl " H H "
4,4-dip~enyl-nrbutyl n CH3 -(CH2)~CH3 "
4,4-diphenyl-n-butyl "nrbutylphenethyl "
diphenylmethyl " Hdiphenylmethyl phenyl 3 CH3 " "
9-fluorenyl 4n-butyl " n 30 4-chic~obenzy1 " H3,3-diphenyl-n-prcpyl "
diphenylmethyl 3 CH3 " "
diphenyIhyd mxymethyl 4 n-butyl Posi-tion of Sub6tit~ent Substi-~ ', or ~ ~) uent ~ ~ A
phenyl(octyl)methyl 4 H H H
10,11-dihydro-5H-dltenzo 2 " -( ~ ) ~ n [a,d]eyclcheF~er-S-yl 3 5~-diben~o[a,d] n ~ n eye1 ~ 5-yl 5 pbenylnhByl)methyl 4 n (~) 6 n E~l (hexyl)~l n mB~yl~ (C82) 4CE~ OE H2CH3 n 10,11-dbhy~e-5H ~ o 2 " -(C ~) C~rH "
[a,d]eye1 ~ -5-yl 6 5E-dlte~zo[a,d] " " " n eyelQheptEn-5-y1 lO,ll~yd~5E~di~zD n ~h~l ~2C3 n [a~d]cyclohept2nr5-yl 10 5H-dikenzo[a,d] " " n cyclQhept~n-5-yl phe~yl(octyl)~ethyl 4 " F~ yl n ~ 5 ~40~l.8 4s Example XVIII
Following t~Q procedure of either Example I or Example III, but substituting for the ethyl formimidate hydrochloride and 4-diphenylmethylpiperidine or N-formyl-5 4-diphenylmethylpiperidine and ethylamine, respectively, used therein, e~uivalent amounts of the appropriate starting materials suc~ as described in Examples XIII
and XVI, there are prepared the following:
(C~2)n ~
~ ~ NC-NR
Position of 10 Su~stituent n ~ R
_ 2 3 3 0 H n-octyl 3 0 H _-dodecyl 4 0 H n-hexadecyl 4 CH3 n-octyl 4 0 n-butyl n-octyl 3 1 H n-octyl 3 1 H n-dodecyl 4 1 H n-hexadecyl 4 1 CH3 n-octyl 4 1 n-butyl n-octyl 3 2 . H H
3 Z H n-octyl 3 2 H n-dodecyl 4 2 H n-hexadecyl 4 2 CH3 n-octyl 4 2 n-butyl n-octyl ~4~
EXAMPLE XIX
Following the procPdure of either Example I or Example III, but suhstituting for the ethyl formimidate hydrochloride and 4-diphenylmethylpiperidine or N-formyl-4-diphenylmethylpiperidine and ethylamine, respectively, used therein, equival~nt amounts of the appropriate starting materials such as descri~ed in Examples XIV
and XVI, there are prepared the following:
\ /
. A~
~ NC--NR3 ~O>
~ H
H n-octyl H n-dodecyl H n-hexadecyl c~3 n-octyl n-butyl n-octyl H H
H n-octyl H n-dodecyl H n-hexadecyl CH3 n-octyl n-butyl n-octyl H H
H n-octyl ~ n-dodecyl H n-hexadecyl CH3 n-octyl n-butyl n-octyl MN.335 1~4V1 18 EXAMPLE XX
Following ~he procedure of either Example I or Example III, but substituting for the ethyl formimidate hydrochloride and ~-diphenylmethylpiperidine or N-formyl-4-diphenylmethylpiperidine and ethylamine, respectively, used therein, e~uivalent amounts of the appropriate starting materials suc~ as described in Examples XV and XVI, there are prepared the following:
(C6H5) 2C~\
\ NC=NR3 Position of 10 Substituent n R2 R3 2 0 H _-octyl 3 0 H _-dodecyl 3 0 H n-hexadecyl 4 0 CH3 n-octyl 4 0 n-butyl n-octyl 2 1 H _-octyl 3 1 H n-dodecyl 3 1 H n-hexadecyl 4 1 CH3 n-octyl 4 1 n-butyl n-octyl 2 2 H n-octyl 3 2 H n-dodecyl 3 2 . H n-hexadecyl 4 2 c~3 n-octyl 4 2 n-butyl n-octyl 114() EXAMPLE XXI
N-[4-(Diphenylmethyl3-1-piperidinyl]
methYlene benzenebutanamine (E)-2-Butenedioate Hvdrate , A ~ixture of 4.40g (0.016 mole) of N-formyl-4-(diphenylmethyl)piperidine and 1.47 ml (2.00g, 0.015 mole) of dimethyl sulfate was heated in a steam bath for three hours at 100C under anhydrous conditions until homo-geneous. The mixture was cooled, dissolved in 30 ml of methylene chloride and treated with 2.50 ml (2.36 g, O.016 mole) of phenylbutylamine. The resulting solution was stirred for three hours and treated with 6 ml 3 N
sodium hydroxide solution with vigorous stirring at 0.
The organic layer wa~ separated, dried over potassium carbonate, filtered and evaporated ~o an oil. This material was dissolved in isopropanol, treated with 1.84g of fumaric acid and cooled. There was filtered off a white crystalline solid which was recrystallized from ethanol to give N-14-(diphenylmethyl)-1-piperidinyl]-methylene benzenebutanamine (E)-2-butenedioate hydrate as a white crystalline solid, m.p. 207-208.5C.
EXAMPLE XXII
~-(Diphenylmethyl)-l- l-[me~hyl(octylimino) methyl]-piperidine Monoperchlorate .
A mixture of the fluoroborate salt of N-octyl-acetimidic acid ethyl ester ~generated from 5.68g [Q~04 molel of boron trifluoride etherate, 2.77g [0.03 mole]
of epichlorohydrin, and 5,80g t~.~34 mole] of N-octyl acetamide) and 5~ ml of ether was treated with 4 ml ~2.92g, 0.029 mole~ of triethyl amine~ Filtratio~ and evaporation of the filtrate afforded a liquid residue whic~ ~as dissolved in 120 ml dry toluene~ To this solution was added 6.00g ~0.024 mole) of glacial acetic acid and the resulting solution was stirred at 50C
over 4A molecular sieves under a nitrogen atmosphere for four days. The reaction mixture was cooled and neutralized by ~haking with 3 N sodium hydroxide solu-tion. The organic layer was separated, dried over X2C03, filtered and stripped to an oil which was distilled.
M~ 33s l~LV~
4g The pot residue was dissolved in ether and perchloric acid and methanol added. Cooling the solution pro-duced a solid fraction. Filtration afforded a crystal-line solid whi.ch was recrystallized three times from S methanol to give 4-(Diphenylmethyl)-l- l-[methyl(octylimino)-methy]~piperidine Monoperchlorate as a white crystalline solid, m.p. 119-121.5C.
EXAMPLE XXIII
a-(4-Methylphenyl ? -a-Phenvl-4-~yridine Methanol A solution of 0.05 le of 4-methylphenyl magnesium bromide in 500 ml of anhydrous ether was treated with 4-benzoylpyridine in S00 ml anhydrous ether.
After stirring the n~lting m~re for 1.5 hc~rs at 25, an ~æ~s soluticn of a~L~ium ~ik~ide was ~ causing a solid to form which waQ filtered. Recrystallization of thi~ material ~rom 95% ethanol afforded the desired ~-(4-methylphenyl)-a-phenyl-4-pyridine methanol, ~.p. 192-135C. The corresponding 4-chlorophenyl (~.p. 198-202C) and 4-methoxyphenyl (~pO 204-206C) derivatives were also prepared by the same method, using equivalent amounts of the appropriate starting materials.
EXAMPLE XXIV
x-(4-Methylphenyl)-a-Phenyl-4-Piperidine A solution of 25~0g (0.09 mole) a-(4-methyl-phenyl~-a-phenyl-4-pyridine methanol, 55 ml of 47-Sl~
hydriodic acid and 180 ml of acetic acid was refluxed overnight, cooled, and poured into aqueous sodium bisulfite. This solution was made basic with sodium hydroxide and extracted with methylene chloride. From the organic layer there was isolated an oil which was reduced at 40 psi over platinum oxide at 60-65C in acetic acid following the method of United States Patent No. 3,267,108. The excess acid was removed and the residue made ba~ic to give a-(4-methylphenyl)-a-phenyl-4-piperidine which was characterized as its fumarate salt, m.p. 157.5-161.5C (Hoover). The corresponding 4-chlorophenyl (m.p. 175-178C; fumarate salt) and ~, ~14 sn 4-methoxyphenyl (m.p. 94-98C; free base3 derivatives were also prepared by the same method, using equivalent amounts of the appropriate star~ing materials.
. EXAMPLE XXV
s -(1,4'-Biphenyl)~l--phenyl-4-pyridinemethanol A solution of 111.0g (0.50 ~ole) of 4-biphenyl bromide in 200 ml of dry ~etrahydrofuran ~THF) was added slowly to a mixture of 12.10g (0.5 gram-atom) of mag-nesium, 2 ml o~ ethylenedibromide and 200 ml of T~F at such a rate as to maintain reflux. After addition the mixture was refluxed for 0.5 hours, cooled and treated over 0.5 hours with a solution of 82.3g (0.45 mole) of 4-benzoylpyridine in 600 ml THF. The resulting slurry was stirred 0.5 hours at 25C and treated with 1000 ml 20% ammonium chloride solution. The organic layer was separated, filtered, the filtrate dried, filtered and stripped. The residue was triturated with ether and filtered. This solid was recrystallized ~rom ethanol, chloroform, and finally toluene to give a-(1,4'-biphenyl)-yl-a-phenyl-4-pyridin methanol as a white solid, m.p.
after drying in vacuo at 70C; 173.5-175.5C.
EXAMPLE XXVI
_ a-(1~4'-Biphenyl)yl-a-phenyl-4-~iperidinemethanol A solution of 10.00g (0.030 mole) of a-(1,4'-biphenyl)yl-a-phenyl-4-pyridine and 160 ml of acetic acid was hydrogenated in the presence of platinum oxide (1.Og) at 25-35 psi at 70-90 on a Paar shaker. After hydrogen uptake ceased, the mixture was filtered through dicalite and evaporated to a solid residue. This residue was slurried in water, made basic with 3 N NaOH and ex-tracted with chloroform. The chloroform layer was dried over potassium carbonate, filtered through dicalite and evaporated. The residue was dissolved in toluene and cooled. The resulting solid was filtered and recrystal-lized from toluene to give a-~1,4'-biphenyl)yl-a-phenyl-4-piperidinemethanol as a white solid; m.p. 185-186.5C.
481.1)3 EXAMPLE XXVII
9-(4'-~ eridinYll-9-fluorenol A sslution of 13.0g (0.05 mole) of 9-(4'-pyridyl)-9-flu~renol in 200 ml of glacial acetic acid was hydrogenated over 0.8g of platinum oxide at 40 psi.
The mixture was filtered, stripped, and the residue made bas~c affording 9-(4'-piperidinyl)-9-fluorenol.
EXAMPLE XXVIII
4-Fluorenylidenepiperidine A suspen~ion of 13.0g (0.05 mole) of 9-(4'-piperidinyl)-9-fluorenol in 70 ml of 48% sulfuric acid was heated on a steam bath for ~even hours and poured on to ice. The resulting solid was filtered, made basic with sodium hydroxide solution and extracted with methylene chloride. The organic layer was qeparated, dried over potassium carbonate, filtered and stripped to give 4-fluorenylidenepiperidine.
EXAMPLE XXIX
9-(4'-Pyridyl)fluorene A solution of 1.35g (0.005 mole1 of ~,a diphenyl-4-pyridine methanol in 18.5 ml of 97% formic acid was treated dropwise with 8 ml of concentrated sulfuric acid.
The r~action was refluxed ten minutes, cooled and made basic with 6 N sodium hydroxide solution causing a solid to separate. This material was filtered and recrystallized from me~hanol to give 9-(4'-pyridyl)fluorene, m.p. 141-143C (Hoover).
EXAMPLE_XXX
9-(4'-PiPeridYl)fluorene fumarate A solution of 54.75g (0.225 mole) of 9-(4'-pyridyl)fluorene in 600 ml of acetic acid was hydro-genated over S.Og of platinum oxide at 40 psi and 25C.
The mixture was filtered, stripped and made basic, afford-ing 9-(4'-piperidyl)fluorene, which was crystallized as the fumarate salt, m.p. 228-230C (dec).
Claims (42)
1. A process for preparing a member selected from the group consisting of a substituted N-iminomethyl-piperidine of formula (I):
(I) and the corresponding non-toxic acid addition salts thereof, wherein:
R1 taken individually is a member selected from the group consisting of hydrogen; phenyl; phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo; phenyl (C1-C4) lower-alkyl; l-phenyl (C7-C9) loweralkyl; phenyl (C1-C4) loweralkyl and l-phenyl (C7-C9) loweralkyl in which said phenyl is substi-tuted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenyl (C1-C4) loweralkyl; diphenyl-(C1-C4) loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae and wherein n is 0, 1, or 2 and E is H or OH;
A taken individually is a member selected from hydrogen, acetyl, and phenyl, provided that when A is acetyl or phenyl, R1 is a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
R1 and A taken together is a member selected from the group consisting of benzhydrylidene and compounds of formulae:
and wherein n is 0, 1, or 2;
R1' taken individually is a member selected from the group consisting of hydrogen; methyl; diphenylmethyl; diphenyl-methyl wherein at least one of the phenyl groups is substituted with from one to three members each selected from the group con-sisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxy-methyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each sel-ected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; and a compound of formula:
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen;
R1' and s taken together is a member selected from the group consisting of benzhydrylidene and a compound of formula:
wherein n is 0, 1, or 2.
R1" taken individually is a member selected from the group consisting of hydrogen, diphenylmethyl; diphenylmethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl;
diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2;
D taken individually is hydrogen;
R1" and D taken together is benzhydrylidene;
R2 is a member selected from the group consisting of hydrogen and C1-C4 loweralkyl; and R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenyllower-alkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; diphenyl (C1-C4) loweralkyl; di-phenyl (C1-C4) loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl;
alkenyl; and alkynyl; provided that at least one of said R1, R1' and R1" is other than hydrogen, and further provided that when R1" is other than hydrogen R1 and R'1 and A are each hydro-gen; when R'1 is hydrogen only one of R1 and R"1 is other than hydrogen; when R'1 is other than hydrogen and R"1 is hydrogen;
and when R'1 is other than hydrogen or ethyl R1, R"1 and A are each hydrogen, characterized by a) i) reacting a compound of formula (II) with a compound of the formula Z? = NR3 (III) or the acid addition salt form of the latter, namely, Z? = NR3 - HX
in a suitable organic solvent at a temperature between 0°C and 50°C, wherein A, B, D, R1, R1', R1, R2, and R3 are as previously defined, Z is selected from the group consisting of loweralkoxy, loweralkyl-S-, chloro, and C12(O)PO-, and X is a member selected from the group consisting of halide, BF4, FSO3, and CH3OSO3, and additionally, when Z is loweralkyl-S-, X may also be a member selected from the group consisting of (4-methylphenyl)SO3, CH3SO3, and CF3SO3 in order to prepare a compound of the formula (I);
or ii) reacting a compound of formula (II) with a compound of the formula R3N=C=S (IIIA) under similar reaction conditions to step a) i) in order to prepare the corresponding thiourea which is then reduced in order to prepare a compound of the formula (I), wherein R2 is hydrogen;
or iii) reacting a compound of formula (II) with a compound of the formula R3N=C (IIIB) in the presence of silver chloride as a catalyst in order to prepare a compound of the formula (I), wherein R2 is hydrogen; or b) i) reacting a compound of the formula X-with a compound of the formula R3NH2 (VII), wherein R1, R1', R1, R2, R3, A, B, D, Z, and X are as defined above, in order to prepare a compound of the formula (I); or ii) in the instance wherein Z in compound (VI) is (loweralkyl)-S- and R2 is H, re-acting said compound of the formula with a compound of the formula R3N=C-O (VIII) in a suitahle solvent, preferably at reflux temperature, in order to prepare a compound of the formula (I), wherein R2 is hydrogen;
and, if desired, preparing non-toxic acid addition salts thereof.
(I) and the corresponding non-toxic acid addition salts thereof, wherein:
R1 taken individually is a member selected from the group consisting of hydrogen; phenyl; phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo; phenyl (C1-C4) lower-alkyl; l-phenyl (C7-C9) loweralkyl; phenyl (C1-C4) loweralkyl and l-phenyl (C7-C9) loweralkyl in which said phenyl is substi-tuted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenyl (C1-C4) loweralkyl; diphenyl-(C1-C4) loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae and wherein n is 0, 1, or 2 and E is H or OH;
A taken individually is a member selected from hydrogen, acetyl, and phenyl, provided that when A is acetyl or phenyl, R1 is a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
R1 and A taken together is a member selected from the group consisting of benzhydrylidene and compounds of formulae:
and wherein n is 0, 1, or 2;
R1' taken individually is a member selected from the group consisting of hydrogen; methyl; diphenylmethyl; diphenyl-methyl wherein at least one of the phenyl groups is substituted with from one to three members each selected from the group con-sisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxy-methyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each sel-ected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; and a compound of formula:
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen;
R1' and s taken together is a member selected from the group consisting of benzhydrylidene and a compound of formula:
wherein n is 0, 1, or 2.
R1" taken individually is a member selected from the group consisting of hydrogen, diphenylmethyl; diphenylmethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl;
diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2;
D taken individually is hydrogen;
R1" and D taken together is benzhydrylidene;
R2 is a member selected from the group consisting of hydrogen and C1-C4 loweralkyl; and R3 is a member selected from the group consisting of hydrogen; alkyl; cycloalkyl; phenylloweralkyl; phenyllower-alkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; diphenyl (C1-C4) loweralkyl; di-phenyl (C1-C4) loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl;
alkenyl; and alkynyl; provided that at least one of said R1, R1' and R1" is other than hydrogen, and further provided that when R1" is other than hydrogen R1 and R'1 and A are each hydro-gen; when R'1 is hydrogen only one of R1 and R"1 is other than hydrogen; when R'1 is other than hydrogen and R"1 is hydrogen;
and when R'1 is other than hydrogen or ethyl R1, R"1 and A are each hydrogen, characterized by a) i) reacting a compound of formula (II) with a compound of the formula Z? = NR3 (III) or the acid addition salt form of the latter, namely, Z? = NR3 - HX
in a suitable organic solvent at a temperature between 0°C and 50°C, wherein A, B, D, R1, R1', R1, R2, and R3 are as previously defined, Z is selected from the group consisting of loweralkoxy, loweralkyl-S-, chloro, and C12(O)PO-, and X is a member selected from the group consisting of halide, BF4, FSO3, and CH3OSO3, and additionally, when Z is loweralkyl-S-, X may also be a member selected from the group consisting of (4-methylphenyl)SO3, CH3SO3, and CF3SO3 in order to prepare a compound of the formula (I);
or ii) reacting a compound of formula (II) with a compound of the formula R3N=C=S (IIIA) under similar reaction conditions to step a) i) in order to prepare the corresponding thiourea which is then reduced in order to prepare a compound of the formula (I), wherein R2 is hydrogen;
or iii) reacting a compound of formula (II) with a compound of the formula R3N=C (IIIB) in the presence of silver chloride as a catalyst in order to prepare a compound of the formula (I), wherein R2 is hydrogen; or b) i) reacting a compound of the formula X-with a compound of the formula R3NH2 (VII), wherein R1, R1', R1, R2, R3, A, B, D, Z, and X are as defined above, in order to prepare a compound of the formula (I); or ii) in the instance wherein Z in compound (VI) is (loweralkyl)-S- and R2 is H, re-acting said compound of the formula with a compound of the formula R3N=C-O (VIII) in a suitahle solvent, preferably at reflux temperature, in order to prepare a compound of the formula (I), wherein R2 is hydrogen;
and, if desired, preparing non-toxic acid addition salts thereof.
2. A process for preparing a member selected from the group consisting of 4-diphenylmethyl-1-iminomethylpiperidine and the non-toxic acid addition salts thereof, characterized by reacting ethyl formimidate with diphenyl-4-piperidylmethane.
3. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1-[(isopropylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, char-acterized by reacting N-formyl-4-diphenylmethylpiperidine with dimethylsulfate and reacting the product with isopropylamine.
4. A process for preparing a member selected from the group consisting of l-[N-(benzyl)iminomethyl]-4-diphenylmethylpiper-idine and the non-toxic acid addition salts thereof, characterized by reacting N-formyl-4-diphenylmethylpiperidine with dimethyl-sulfate and reacting the product with benzylamine.
5. A process for preparing a member selected from the group consisting of l-[N-(phenethyl)iminomethyl]-4-diphenylmethylpiper-idine and the non-toxic acid addition salts thereof, character-ized by reacting N-formyl-4-diphenylmethylpiperidine with di-methyl sulfate and then reacting the product with phenethylamine.
6. A process for preparing a member selected from the group consisting of 1-[N-(n-decyl)iminomethyl]-4-diphenylmethylpiper-idine and the non-toxic acid addition salts thereof, character-ized by reacting N-formyl-4-diphenylmethylpiperidine with di-methyl sulfate and then reacting the product with n-decylamine.
7. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1 [octylimino)methyl]piperidine and the non-toxic acid addition salts thereof, characterized by reacting N-formyl-4-diphenylmethylpiperidine with phosgene and then reacting the product with octylamine.
8. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1-[(2-propynylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, char-acterized by reacting 4-(diphenylmethyl)-1-piperidinocarbothioal-dehyde with methyl iodide and reacting the product with 2-propy-nylamine.
9. A process for preparing a member selected from the group consisting of 4-benzhydrylidene-1-[(octylimino)methy] piperidine and the non-toxic acid addition salts thereof, characterized by reacting 4-benzhydrylidene-1-piperidinecarbothioaldehyde with methyl iodide and then reacting the product with n-octylamine.
10. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1-[(ethylimino)methyl] piper-idine and the non-toxic acid addition salts thereof, character-ized by reacting ethylpropionimidate hydrochloride with diphenyl-4-piperidylmethane.
11. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1-[(hexylimino)methyl] piperidine and the non-toxic acid addition salts thereof, characterized by reacting N-formyl-4-diphenylmethylpiperidine with dimethyl sul-fate and then reacting the product with hexylamine.
12. A process for preparing a member selected from the group consisting of 1-[(4-chlorobenzylimino)methyl]-4-(diphenylmethyl)-piperidine and the non-toxic acid addition salts thereof, char-acterized by reacting N-formyl-4-diphenylmethylpiperidine with dimethyl sulfate and then reacting the product with 4-chloro-benzylamine.
13. A process for preparing a member selected from the group consisting of 4[1-(4-methoxyphenyl)benzyl]-1-[(octylimino)-methyl]-piperidine and the non-toxic acid addition salts there-of, characterized by reacting N-formyl-4 [1-(4-methoxyphenyl)-benzyl] -piperidine with dimethyl sulfate and then reacting the product with octylamine.
14. A process for preparing a member selected from the group consisting of 4[l-[4-chlorophenyl)benzyl]-l-iminomethylpiperi-dine and the non-toxic acid addition salts thereof, character-ized by reacting ethyl formidate hydrochloride with 4-[.alpha.-(4-chlorophenyl)benzyl] piperidine.
15. A process for preparing a member selected from the group consisting of 4(9-fluorenyl)-1-[(octylimino)methyl]piperidine and the non-toxic acid addition salts thereof, characterized by reacting 4(9-fluorenyl)-1-piperidinecarbothioaldehyde with methyl iodide and then reacting the product with octylamine.
16. A process for preparing a member selected from the group consisting of 4-(diphenylmethyl)-1-[methyl(octylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, char-acterized by reacting triethyloxoniumfluoroborate with N-(n-octyl)acetamide and reacting the product with 4-diphenylmethyl-piperidine.
17. A process for preparing a member selected from the group consisting of N-[4-(diphenylmethyl)-1-piperidinyl]methylene benzenebutylimine and the non-toxic acid addition salts thereof, characterized by reacting N-formyl-4-diphenylmethylpiperidine with dimethyl sulfate and then reacting the product with phenyl-butylamine.
18 . A process for preparing a member selected from the group consisting of 3-(diphenylmethyl)-1-[(octyl-imino)methyl]piperidine and the non-toxic acid addition salts thereof, characterized by reacting 3-(diphenyl-methyl)-l-piperidinecarbothioaldehyde with methyliodide and then reacting the product with octylamine.
19. A process for preparing 4-(hydroxydiphenylmethyl)-1-[(octylimino)methyl]piperidine(E)-2-butenedioate, characterized by reacting 4-(hydroxydiphenylmethyl)-1-piperidinecarbothioaldehyde with methyliodide and then reacting the product with octylamine.
20. A process for preparing 3-(diphenylmethyl)-1-(iminomethyl)piperidine(E)-2-butenedioate hydrate, characterized by reacting 3-(diphenylmethyl)-1-piperidinecarbothioaldehyde with methyl iodide and aminating the product.
21. A process for preparing 4-[4-hydroxyphenyl)phenyl-methyl]-1-[octylimino)methyl]piperidine 2-naphthalene-sulfonate, characterized by treating 4-[(4-methoxyphenyl) phenylmethyl]-1-[(octylimino)methyl]piperidine with hydrobromic acid and converting the obtained product to its 2-naphthalenesulfonic acid salt.
22. A member selected from the group consisting of a substituted N-iminomethylpiperidine of formula (I):
(I) and the corresponding non-toxic acid addition salts thereof, wherein:
R1 taken individually is a member selected from the group consisting of hydrogen; phenyl;
phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, hydroxy and halo; phenyl (C1-C4)loweralkyl;
l-phenyl(C7-C9)loweralkyl; phenyl(C1-C4)lowaralkyl and l-phenyl(C7-C9)loweralkyl in which said phenyl is sub-stituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenyl(C1-C4)loweralkyl; diphenyl-(C1-C4)loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl;
diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralXoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2 and E is H or OH;
A taken individually is a member selected from hydrogen, acetyl, and phenyl, provided that when A is acetyl or phenyl, R1 is a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
R1 and A taken together is a member selected from the group consisting of benzhydrylidene and compounds of formulae:
and wherein n is 0, 1, or 2;
R1' taken individually is a member selected from the group consisting of hydrogen; methyl; diphenylmethyl, diphenyl-methyl wherein at least one of the phenyl groups is sub-stituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenyl-hydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; and a compound of formula:
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen R1' and B taken together is a member selected from the group consisting of benzhydrylidene and a compound of formula wherein n i8 0, 1, or 2 R1" taken individually is a member selected from the group consisting of hydrogen, diphenylmethyl; diphenylmethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, pro-vided that no more than one member is phenyl; diphenyl-hydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one of three members each selected from the group consisting of lower-alkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2;
D taken individually is hydrogen;
R; and D taken together is benzhydrylidene;
R2 is a member selected from the group con-sisting of hydkogen and C1-C4 loweralkyl; and R3 is a member selected from the group con-sisting of hydrogen alkyl; cycloalkyl; phenylloweralkyl;
phenylloweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; di-phenyl(C1-C4)loweralkyl; diphenyl(C1-C4)loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; alkenyl; and alkynyl; provided that at least one of said R1, R1', and R1" is other than hydrogen and further provided that when R1" is other than hydrogen R1, and R'1, and A are each hydrogen; when R'1 is hydrogen only one of R1 and R"1 is other than hydrogen; when R'1 is other than hydrogen or ethyl R1, R"1 and A are each hydrogen whenever prepared or produced by the process of claim 1 or by any chemical equivalent thereof.
(I) and the corresponding non-toxic acid addition salts thereof, wherein:
R1 taken individually is a member selected from the group consisting of hydrogen; phenyl;
phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, lower-alkoxy, hydroxy and halo; phenyl (C1-C4)loweralkyl;
l-phenyl(C7-C9)loweralkyl; phenyl(C1-C4)lowaralkyl and l-phenyl(C7-C9)loweralkyl in which said phenyl is sub-stituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenyl(C1-C4)loweralkyl; diphenyl-(C1-C4)loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl;
diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralXoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2 and E is H or OH;
A taken individually is a member selected from hydrogen, acetyl, and phenyl, provided that when A is acetyl or phenyl, R1 is a member selected from the group consisting of phenyl or phenyl substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy and halo;
R1 and A taken together is a member selected from the group consisting of benzhydrylidene and compounds of formulae:
and wherein n is 0, 1, or 2;
R1' taken individually is a member selected from the group consisting of hydrogen; methyl; diphenylmethyl, diphenyl-methyl wherein at least one of the phenyl groups is sub-stituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; diphenylhydroxymethyl; diphenyl-hydroxymethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; and a compound of formula:
wherein n is 0, 1, or 2 and E is H or OH;
B taken individually is hydrogen R1' and B taken together is a member selected from the group consisting of benzhydrylidene and a compound of formula wherein n i8 0, 1, or 2 R1" taken individually is a member selected from the group consisting of hydrogen, diphenylmethyl; diphenylmethyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, pro-vided that no more than one member is phenyl; diphenyl-hydroxymethyl; diphenylhydroxymethyl wherein at least one of said phenyls is substituted with from one of three members each selected from the group consisting of lower-alkyl, loweralkoxy, hydroxy, halo, and phenyl, provided that no more than one member is phenyl; and compounds of formulae:
and wherein n is 0, 1, or 2;
D taken individually is hydrogen;
R; and D taken together is benzhydrylidene;
R2 is a member selected from the group con-sisting of hydkogen and C1-C4 loweralkyl; and R3 is a member selected from the group con-sisting of hydrogen alkyl; cycloalkyl; phenylloweralkyl;
phenylloweralkyl in which said phenyl is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, hydroxy, and halo; di-phenyl(C1-C4)loweralkyl; diphenyl(C1-C4)loweralkyl wherein at least one of said phenyls is substituted with from one to three members each selected from the group consisting of loweralkyl, loweralkoxy, halo, hydroxy, and phenyl, provided that no more than one member is phenyl; alkenyl; and alkynyl; provided that at least one of said R1, R1', and R1" is other than hydrogen and further provided that when R1" is other than hydrogen R1, and R'1, and A are each hydrogen; when R'1 is hydrogen only one of R1 and R"1 is other than hydrogen; when R'1 is other than hydrogen or ethyl R1, R"1 and A are each hydrogen whenever prepared or produced by the process of claim 1 or by any chemical equivalent thereof.
23. A member selected from the group consisting of 4-diphenyl-methyl-l-iminomethylpiperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 2 or by any chemical equivalent thereof.
24. A member selected from the group consisting of 4-(diphenyl-methyl-l- [(isopropylimino)methyl] piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 3 or by any chemical equivalent thereof.
25. A member selected from the group consisting of l-[N-(benzyl)iminomethyl]-4-diphenylmethylpiperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 4 or by any chemical equivalent thereof.
26. A member selected from the group consisting of l-[N-(phenethyl)iminomethyl]-4-diphenylmethylpiperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 5 or by any chemical equivalent thereof.
27. A member selected from the group consisting of l-[N-(n-decyl)iminomethyl]-4-diphenylmethylpiperidine and the non-toxic acid additions salts thereof, whenever prepared or produced by the process of Claim 6 or by any chemical equivalent thereof.
28. A member selected from the group consisting of 4-(diphenyl-methyl)-l- [(octylimino)methyl] piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 7 or by any chemical equivalent thereof.
29. A member selected from the group consisting of 4-(diphenyl-methyl)-l-[(ethylimino)methyl]piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 10 or by any chemical equivalent thereof.
30. A member selected from the group consisting of 4-(diphenyl-methyl)-l-[(hexylimino)methyl] piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 11 or by any chemical equivalent thereof.
31. A member selected from the group consisting of 1-[(4-chlorobenzylimino)methyl]-4-(diphenylmethyl)-piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 12 or by any chemical equivalent thereof.
32. A member selected from the group consisting of 4-(diphenyl-methyl)-l-[(2-propynylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 8 or by any chemical equivalent thereof.
33. A member selected from the group consisting of 4[1-(4-methoxyphenyl)benzyl]-1-[(octylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, whenever prepared or pro-duced by the process of Claim 13 or by any chemical equivalent thereof.
34. A member selected from the group consisting of 4[1-(4-chlorophenyl)benzyl]-l-iminomethylpiperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Clalm 14 or by any chemical equivalent thereof.
35. A member selected from the group consisting of 4(9-fluo-renyl)-l-[(octylimino)methyl] piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 15 or by any chemical equivalent thereof.
36. A member selected from the group consisting of 4-(diphenyl-methyl)-l-[methyl(octylimino)methyl]-piperidine and the non-toxic acid addition salts thereof, prepared or produced by the process of Claim 16 or by any chemical equivalent thereof.
37. A member selected from the group consisting of N-[4-(di-phenylmethyl)-l-piperidinyl] methylene benzenebutylimine and the non-toxic acid addition salts thereof, whenever prepared or pro-duced by the process of Claim 17 or by any chemical equivalent thereof.
38. A member selected from the group consisting of 4-benzhydry-lidene-l-[(octylimino)methyl]piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 9 or by any chemical equivalent thereof.
39. A member selected from the group consisting of 3-(diphenyl-methyl)-1-[(octylimino)methyl] piperidine and the non-toxic acid addition salts thereof, whenever prepared or produced by the process of Claim 18 or by any chemical equivalent thereof.
40. A member selected from the group consisting of 4-(hydroxydiphenylmethyl)-1-[(octylimino)methyl]
piperidine(E)-2-butenedioate and the non-toxic addition salts thereof , whenever prepared or produced by the process of Claim 19 or by any chemical equivalent thereof.
piperidine(E)-2-butenedioate and the non-toxic addition salts thereof , whenever prepared or produced by the process of Claim 19 or by any chemical equivalent thereof.
41. A member selected from the group consisting of 3-(diphenylmethyl)-1-(iminomethyl)piperidine(E)-2-butenedioate hydrate, and the non-toxic addition salts thereof , whenever prepared or produced by the process of Claim 20 or by any chemical equivalent thereof.
42. A member selected from the group consisting of 4-[(4-hydroxyphenyl)phenylmethyl]-1-[(octylimino)methyl]
piperidine 2-naphthalenesulfonate or the non-toxic addition salts thereof, whenever prepared or produced by the process of Claim 21 or by any chemical eauivalent thereof.
piperidine 2-naphthalenesulfonate or the non-toxic addition salts thereof, whenever prepared or produced by the process of Claim 21 or by any chemical eauivalent thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89141978A | 1978-03-29 | 1978-03-29 | |
| US891,419 | 1978-03-29 | ||
| US1020979A | 1979-02-08 | 1979-02-08 | |
| US10,209 | 1979-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1140118A true CA1140118A (en) | 1983-01-25 |
Family
ID=26680913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000324324A Expired CA1140118A (en) | 1978-03-29 | 1979-03-28 | Substituted n-iminomethylpiperidines |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS54132580A (en) |
| AT (1) | AT372081B (en) |
| AU (1) | AU523867B2 (en) |
| CA (1) | CA1140118A (en) |
| CH (1) | CH639071A5 (en) |
| DE (1) | DE2912026A1 (en) |
| DK (1) | DK124979A (en) |
| ES (1) | ES479033A1 (en) |
| FI (1) | FI791035A7 (en) |
| FR (1) | FR2421169A1 (en) |
| GB (1) | GB2017689B (en) |
| GR (1) | GR65192B (en) |
| IE (1) | IE47898B1 (en) |
| IL (1) | IL56962A (en) |
| IT (1) | IT1116525B (en) |
| NL (1) | NL7902465A (en) |
| NO (1) | NO791026L (en) |
| NZ (1) | NZ189977A (en) |
| PH (1) | PH15760A (en) |
| PT (1) | PT69383A (en) |
| SE (1) | SE7902724L (en) |
| SU (1) | SU1158042A3 (en) |
| YU (1) | YU73179A (en) |
| ZW (1) | ZW6479A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| SE508513C2 (en) * | 1997-02-14 | 1998-10-12 | Ericsson Telefon Ab L M | Microstrip antenna as well as group antenna |
| TWI245763B (en) * | 1998-04-02 | 2005-12-21 | Janssen Pharmaceutica Nv | Biocidal benzylbiphenyl derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH563109A5 (en) * | 1972-03-17 | 1975-06-30 | Ciba Geigy Ag |
-
1979
- 1979-03-19 AU AU45322/79A patent/AU523867B2/en not_active Ceased
- 1979-03-20 GB GB7909671A patent/GB2017689B/en not_active Expired
- 1979-03-22 PT PT69383A patent/PT69383A/en unknown
- 1979-03-23 NZ NZ189977A patent/NZ189977A/en unknown
- 1979-03-27 DK DK124979A patent/DK124979A/en not_active Application Discontinuation
- 1979-03-27 JP JP3516879A patent/JPS54132580A/en active Granted
- 1979-03-27 YU YU00731/79A patent/YU73179A/en unknown
- 1979-03-27 DE DE19792912026 patent/DE2912026A1/en active Granted
- 1979-03-27 SE SE7902724A patent/SE7902724L/en not_active Application Discontinuation
- 1979-03-28 IT IT48515/79A patent/IT1116525B/en active
- 1979-03-28 SU SU792745899A patent/SU1158042A3/en active
- 1979-03-28 AT AT0230979A patent/AT372081B/en not_active IP Right Cessation
- 1979-03-28 ES ES479033A patent/ES479033A1/en not_active Expired
- 1979-03-28 PH PH22331A patent/PH15760A/en unknown
- 1979-03-28 ZW ZW64/79A patent/ZW6479A1/en unknown
- 1979-03-28 IL IL56962A patent/IL56962A/en unknown
- 1979-03-28 CA CA000324324A patent/CA1140118A/en not_active Expired
- 1979-03-28 NO NO791026A patent/NO791026L/en unknown
- 1979-03-28 FI FI791035A patent/FI791035A7/en not_active Application Discontinuation
- 1979-03-29 GR GR58719A patent/GR65192B/en unknown
- 1979-03-29 NL NL7902465A patent/NL7902465A/en not_active Application Discontinuation
- 1979-03-29 CH CH292779A patent/CH639071A5/en not_active IP Right Cessation
- 1979-03-29 FR FR7907919A patent/FR2421169A1/en active Granted
- 1979-08-08 IE IE650/79A patent/IE47898B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4532279A (en) | 1979-10-04 |
| IL56962A0 (en) | 1979-05-31 |
| DK124979A (en) | 1979-09-30 |
| FR2421169A1 (en) | 1979-10-26 |
| IE47898B1 (en) | 1984-07-11 |
| SU1158042A3 (en) | 1985-05-23 |
| FR2421169B1 (en) | 1983-05-27 |
| GB2017689B (en) | 1982-09-02 |
| IT1116525B (en) | 1986-02-10 |
| AT372081B (en) | 1983-08-25 |
| IL56962A (en) | 1983-03-31 |
| FI791035A7 (en) | 1981-01-01 |
| NL7902465A (en) | 1979-10-02 |
| NO791026L (en) | 1979-10-02 |
| GB2017689A (en) | 1979-10-10 |
| PT69383A (en) | 1979-04-01 |
| PH15760A (en) | 1983-03-22 |
| YU73179A (en) | 1983-12-31 |
| DE2912026C2 (en) | 1990-04-05 |
| ATA230979A (en) | 1983-01-15 |
| NZ189977A (en) | 1984-05-31 |
| IT7948515A0 (en) | 1979-03-28 |
| JPS54132580A (en) | 1979-10-15 |
| JPS6217588B2 (en) | 1987-04-18 |
| AU523867B2 (en) | 1982-08-19 |
| IE790650L (en) | 1979-09-29 |
| DE2912026A1 (en) | 1979-10-11 |
| ZW6479A1 (en) | 1980-11-26 |
| ES479033A1 (en) | 1980-06-16 |
| GR65192B (en) | 1980-07-29 |
| CH639071A5 (en) | 1983-10-31 |
| SE7902724L (en) | 1979-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3714159A (en) | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides | |
| CA1059512A (en) | 1-substituted-4-benzylpiperidines | |
| EP0506468B1 (en) | N-substituted 4-phenyl-piperidine opioid-antagonists | |
| US3884916A (en) | 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides | |
| US3922276A (en) | 1-Substituted-4-benzylidenepiperidines | |
| US2846437A (en) | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof | |
| DE2819210A1 (en) | 4-AMINOMETHYL-1- (3,3,3-TRIARYLPROPYL) -4-ARYLPIPERIDINE AND ITS DERIVATIVES | |
| DE2311570A1 (en) | 4-AMINOCHINOLINES, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| HU178532B (en) | Process for producing 1,2,4,5-tetraalkyl-4-aryl-piperidine derivatives | |
| US4251655A (en) | Substituted N-iminomethylpiperidines | |
| EP0325406B1 (en) | Diamine compounds | |
| CA1140118A (en) | Substituted n-iminomethylpiperidines | |
| US4540780A (en) | Diphenylmethylene piperidines | |
| EP0005607A1 (en) | Xanthone and thioxanthone derivatives, their preparation and pharmaceutical compositions containing them | |
| DE2628570C3 (en) | ||
| FI74950B (en) | FOERFARANDE FOER FRAMSTAELLNING AV THERAPEUTISKT AKTIVA 2- / 4- (DIPHENYLMETHYLENE) -1-PIPERIDINYL ACETYXYROR. | |
| CA1086742A (en) | Preparation of 1-substituted-4-aroyl-4-hydroxy and -4- acyloxypiperidines | |
| US3371093A (en) | N-lower-alkyl and n-substituted-lower-alkyl-n-(and n, n-bis-)[(1-piperidyl)-lower-alkyl]amines | |
| US4666905A (en) | Diphenylmethylene piperidines compositions and methods for their use | |
| WO1995024390A1 (en) | Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists | |
| US3575990A (en) | 4-ar3-1-(4-ar1-4-ar2-butyl)-4-hydroxy-piperidines | |
| CA1175048A (en) | 2-cyclic amino-2-(1,2-benzisoxazol-3-yl)-acetic acid ester derivatives | |
| CA2047389C (en) | Substituted piperidines and their use as inhibitors of cholesterol synthesis | |
| US2901487A (en) | Certificate of correction | |
| HU179982B (en) | Process for preparing azacycloalkane and azacycloalkene derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |